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GENERAL INTRODUCTION 
 
 
THE EXTRACELLULAR MATRIX 
The development of an extracellular matrix 
(ECM) has played a pivotal role in the 
evolution of multicellular organisms. It 
imparts strength, resilience and structure to 
tissues and provides a framework for cells. 
There are essentially four types or major 
macromolecules in the ECM; collagens, 
elastin (a major component of the elastic 
fibers), glycoproteins and proteoglycans. 
Collagen fibrils provide strength to the ECM 
while elastic fibers define the stretch and 
recoil properties of a tissue. The 
composition and structure of the ECM is 
highly dependant on the function of the 
tissue. While the cells determine the ECM 
around them, the cells themselves are 
influenced by components of the ECM or 
changes therein. This gives rise to a highly 
complex tissue specific aggregate of 
macromolecules essential for structure and 
development of animals. 
 
COLLAGENS 
Collagens are abundantly expressed in the 
ECM. They provide strength and structure to 
skin, ligaments, blood vessels, cartilage, 
bone and most other connective tissues. 
Collagens are characterised by triple helical 
domains, which are composed of three 
polypeptide chains (α-chains). The 
polypeptide chains can be identical 
(homotrimers) or genetically distinct 
(heterotrimers). The collageneous triple 
helix is made possible by a specific 
repeating sequence of glycine-X-Y were in 
most instances X and Y are proline and 
hydroxyproline. The formed triple helix is a 
semi-rigid domain; therefore collagens are 
flexible, rod like molecules. Thus far 28 
different collagen types have been 
identified. Based on the triple helix size, 
physical, physiological and chemical 
properties collagens can be divided into 
several groups.  
Fibrillar collagens (type I, II, III, V, XI, 
XXIV and XXVII) [1-4] are the largest group 
of collagens and form long unbranched 
fibrils of stacked collagen (triple helical) 
molecules. Fibril composition and 
aggregation is dependant on the type of 
collagen. Collagen types II, XI and XXVII are 
predominantly expressed in cartilage, while 
types I, III, V and XXIV are expressed in 
most other tissues. Fibrillar collagens self- 
assemble into correctly stacked fibrils of 
67nm axial periodicity (D) in vitro [5-8]. 
However, the organisation of the fibrils into 
higher-order structures is only present in 
vivo. The molecular details of fibril assembly 
are not yet completely understood, although 
it appears highly regulated in the fibroblasts. 
Briefly, procollagen is cotranslationally 
translocated into the lumen of the 
endoplasmatic reticulum (ER) were a 
number of enzymes and chaperones assist 
in the trimerization and folding. The C-
terminal propetide of procollagen ensures 
association of three appropriate 
procollagens. The collagen triple helix self 
assembles in the C-to-N-terminal direction. 
A large number of post-translational 
modifications occur in the ER. Hydroxylation 
of proline and lysine residues is an 
important step in the process as 
hydroxyproline stabilizes the triple helix and 
hydroxylysine is important in intra- and inter 
molecular crosslinks between fibrils through 
the actions of lysyl oxidase. Removal of the 
C- and N-terminal propetides occurs after 
transport of procollagen across the Golgi 
stacks. By removing the C-terminal 
propeptide collagen molecules are triggered 
to self-assemble into fibrils. Golgi-to-plasma 
membrane carriers transport one or more 
collagen fibrils to the plasma membrane 
where they are deposited into the ECM. 
Collagen fibril growth takes place by end-to-
end fusion of collagen fibrils to other 
collagen fibrils or at the base of the fibril by 
addition of individual collagen molecules. 
The fibrils subsequently form collagen fibril 
bundles that are organised into higher-order 
structures [1;8-10]. 
Non-fibrillar collagens can be divided 
into several subgroups based on their 
structure and (bio)chemical properties, 
however, the exact function of these 
collagens is not always known. FACIT (fibril-
associated collagens with interrupted triple 
helices, types IX, XII, XIV, XVI, XIX) mostly 
function as linkers between collagen fibrils 
and other ECM molecules. Collagens type 
XX and XXI may be associated with 
collagen fibrils and type XXII with 
microfibrils. The short chain collagens (type 
VI VIII X) are microfibril forming collagens. 
They also contain a putative cell binding 
sequence; RGD (arginine-glycine-aspartic 
acid) [1;11-15]. Collagen XXVI consists of 
two collagenous domains interrupted by 
three non-collagenous domains. It is 
expressed in testis and ovary, although its 
function is not yet fully understood [16].
 Basement membrane collagens type 
IV and VII are collagenous components of 
the basement membrane. Their function is 
to anchor the basement membrane to 
underlying structures. Collagens type XV 
and XVIII are collagens with multiple 
interrupted triple helical domains that are 
associated with basement membrane 
zones, possibly providing structure and 
integrity to the basement membrane. 
Cleaved products form antiangiogenic 
fragments restin (from type XV) and 
endostatin (from type XVIII). The function of 
the newly discovered collagen type XXVIII is 
not known, although it possibly has a role in 
nerve fibre basement membrane assembly 
[1;17;18].  
Type XIII, XVII, XXIII and XXV are 
transmembrane collagens. They are an 
integral part of the plasma membrane. 
Collagen type XVII is a component of 
hemidesmosomes, while collagen type XIII 
is expressed ubiquitously. Collagen XXIII 
was identified in tumor cells and thought to 
be involved in cell-cell interactions. A 
cleaved form of collagen type XXV is 
present in the amyloid plaques in 
Alzheimer’s disease [1;17;19;20]. 
 
 
 
ELASTIC FIBERS 
Tissue flexibility and extensibility are 
essential requirements in dynamic elastic 
connective tissues such as skin, tendons, 
lung and blood vessels. Elastic fibers are 
insoluble macromolecular structures that 
give resilience and the ability to stretch and 
recoil to connective tissue. Elastogenesis is 
a complex process that is not completely 
understood. The main components of elastic 
fibers are microfibrils composed of fibrillin-1 
and -2 and an amorphous core of elastin.  
However, a large number of other ECM 
molecules are thought to be associated with 
or incorporated into the elastic fibers 
including fibulins, emilins, collagens and 
proteoglycans. Microfibril assembly is a cell-
regulated process and independent of the 
tropoelastin pathway. Fibrillin is excreted by 
the cell and linear fibrillin arrays are formed 
on the cell surface. In this process calcium 
plays an important role in the folding of 
fibrillin. The fibrillin arrays are deposited in 
the ECM were they undergo maturation into 
beaded transglutaminase crosslinked 
microfibrils. The microfibrils form crosslinked 
microfibril bundles, which act as a scaffold 
for tropoelastin, the soluble precursor of 
elastin. Newly synthesized elastin is 
deposited onto the microfibrils, were it forms 
the core of an elastic fibre. In vitro elastin 
can self-assemble by a process called 
coascervation into an aggregate resembling 
the configuration of elastic fibre core in vivo. 
In vivo however, the tropoelastin is 
crosslinked by lysyl-oxidase-like proteins 
LOX and LOXL resulting in (mature) elastin 
with unique desmosine and isodesmosine 
crosslinks. The crosslinked elastin forms the 
core of the elastic fiber and is surrounded by 
microfibrillar bundles [21-31].  
The elastic fibers’ shape, deposition 
and function differ depending on the tissue, 
location and species, as illustrated by three 
examples. The elastic fibers in the reticular 
dermis of human skin are thick horizontally 
arranged fibers. The papillary dermis 
contains thin perpendicular orientated 
(candela structure) elastic fibers (elaunin 
fibers) that merge with a microfibrillar 
cascade (oxytalan fibers). Such organization 
cannot be found in most other mammals, 
except for pig. In the skin of most mammals 
and avian species the elastic fibers perform 
a primary role in the movement of skin 
covering (hairs, feathers). In the aorta the 
elastic fibers form thick concentric lamellae 
giving resilience to the blood vessel. 
Relative little elastic fibers are present in 
tendons while they are abundant in flexible 
ligaments. In most tissues elastic fibers are 
designed to last a lifetime and only limited 
remodelling is possible. Elastic fibers are 
susceptible to a certain degree of 
degradation by enzymes such as neutrophil 
elastase and matrix metalloproteinases, 
which can lead to loss of elasticity of tissue 
in age dependant processes or sun induced 
elastosis [22;32-34]. 
 
TENASCINS 
Tenascin-X is one member of a family of 
ECM glycoproteins that share a common 
general structure, but are distinguished by 
their patterns of expression in development 
and disease [35].  Tenascins consist of a N-
terminal globular domain and heptad 
repeats, which facilitate multimerization; a 
number of epidermal growth factor (EGF) 
like repeats, a series of fibronectin type III 
(FNIII) repeats, and a C-terminal fibrinogen 
domain. There are four mammalian 
tenascins, each identified by more than one 
laboratory, leading to a variety of names 
depending on the context of discovery. For 
clarity, the mammalian genes are now called 
tenascin-C (TNC, formerly cytotactin, 
hexabrachion), tenascin-R (TNR, restrictin, 
janusin), tenascin-X (TNX, also tenascin-Y 
in chick), and the recently described 
tenascin-W (TNW, also tenascin-N) (figure 
1) [36-46]. While many possible functions for 
these proteins have been proposed based 
on patterns of expression and studies in 
vitro, their functions in vivo remain poorly 
understood.  
 
 
 
Figure 1: Mammalian tenascins. 
Tenascins consist of a N-terminal globular domain and heptad repeats, which facilitate multimerization, a number of 
epidermal growth factor (EGF) like repeats, a series of fibronectin type III (FNIII) repeats, and a C-terminal fibrinogen 
domain. TNC has 14.5 EGF-like repeats and up to 15 FNIII repeats. TNR consists of 4.5 EGF-like repeats and 9 FNIII 
repeats. TNX, the largest tenascin thus far discovered, encompasses 18.5 EGF-like repeats and 29 to 32 FNIII 
repeats, depending on the species. Tenascin-W, identified in mice, has 3.5 EGF-like repeats and 9 FNIII repeats.  
 
 
The findings that the TNC, TNR, and 
TNC/TNR double knockout mice lack an 
overt phenotype was both surprising and 
disappointing [47-49], and it remains 
uncertain whether this reflects redundant 
functions shared by the tenascins or 
whether the most important functions of 
these proteins are not during development 
but in adult responses to stress or injury. It 
was on this background, that the initial 
association of TNX deficiency with human 
Ehlers-Danlos syndrome (EDS) was made 
[50]. This observation was of particular 
interest not only because it revealed unique 
functions for at least one tenascin, but also 
because it demonstrated that genes beyond 
the fibrillar collagens and collagen modifying 
enzymes can cause EDS [51;52].  
 
DISCOVERY OF TENASCIN-X 
TNX was identified serendipitously because 
of its 3’ overlap with the human CYP21B 
gene [38]. CYP21B encodes steroid 21-
hydroxylase, an essential enzyme in cortisol  
 
and mineralocorticoid biosynthesis, 
deficiency of which leads to the recessive 
disorder, congenital adrenal hyperplasia 
(CAH) [53]. While trying to clone a mutant 
CYP21B cDNA from an adrenal library 
prepared from the adrenal gland of an 
affected fetus, Morel et al. [38] instead 
cloned a transcript overlapping CYP21B, but 
arising from the opposite DNA strand. This 
transcript was of low abundance that 
escaped previous recognition because of 
the 100-fold greater expression of CYP21B 
in the normal adrenal. Further analysis of 
this genomic locus on chromosome 6 
showed that this transcript arose from a 
gene (TNX) that was partially duplicated 
along with CYP21 and C4 encoding the 4th 
component of serum complement. As shown 
in figure 2, these genes are arranged in the 
order: C4A/CYP21A/XA/C4B/CYP21B/TNX 
(fig. 2). Both C4 genes are functional, while 
only the CYP21B gene is functional in 
humans.  
 
 
 
 
 
Figure 2: Deletions in the C4/CYP21/TNX locus.  
The top panel shows the order of genes in this locus on human chromosome 6. The duplication event created 
complete duplicate copies of C4 and CYP21 and a partial duplicate of TNX (called XA). CYP21A and XA are non-
functional pseudogenes. Unequal crossover events can occur through mis-alignment of the A and B regions during 
meiosis and produce alleles missing one 30 kb C4/CYP/TNX cassette. X1: Crossover between C4 genes reduces C4 
copy number, but is otherwise without effect. X2: Crossover between CYP21 genes inactivates CYP21B but TNX is 
unaffected. X3: Crossover between TNX and XA deletes CYP21B entirely and inactivates TNX because the small 
deletion in XA (d) truncates its open reading frame. This allele is associated with a contiguous gene syndrome 
consisting of congenital adrenal hyperplasia and EDS. 
  
The duplication event truncated the 
duplicate TNX gene (called XA), which also 
contains a 121 basepair deletion that 
interrupts its open reading frame, rendering 
it non-functional [54]. Surprisingly, the XA 
gene is transcribed in the adrenal gland, but 
does not appear to encode protein [55]. 
However, a short adrenal specific transcript 
of TNX (XB-S) does encode protein [56].  
Following this initial report, Matsumoto et al. 
[57] identified a cluster of fibronectin type III 
repeats in the class III region of the MHC 
that clearly represented an upstream portion 
of the TNX gene. Reports of the complete 
human gene and mouse cDNA soon 
followed, and included studies of expression 
that were consistent with important roles in 
development and matrix biology [40;41;57-
59]. However, the large size of the TNX 
mRNA (12 kb) and protein (450 kDa) 
impeded functional studies and suggested 
to us that genetic strategies were most likely 
to identify unique functions for TNX. 
 
THE EHLERS-DANLOS SYNDROME 
The Ehlers-Danlos syndrome (EDS) is a 
heterogeneous group of heritable 
connective tissue disorders characterized by 
joint hypermobility and various degrees of 
tissue fragility.  The classification of EDS is 
made according to the “1997 Villefranche 
nosology”, which recognizes six major 
types. Classification of EDS is made on 
clinical grounds, biochemical and molecular 
analysis and mode of inheritance.  The two 
most prevalent EDS types are the classical 
and hypermobility type EDS. Classical type 
EDS is characterised by joint hypermobility, 
skin hyperextensibility, poor wound healing 
with athropic scarring and easy bruising. 
Only 50% of the cases of classical type EDS 
can be explained by mutations in the 
COL5A1, COL5A2 and COL1A1 genes 
while the remainder of the mutations is 
unknown. Hypermobility type EDS is 
characterised by joint hypermobility and 
hyperextensible or smooth velvety skin. 
Often patients suffer from chronic 
musculoskeletal pain. The causative genetic 
defects are largly unknown. Vascular type 
EDS is the most severe and life-threatening 
type of EDS. Patients have thin translucent 
skin and fragile tissues resulting in the 
rupture of aorta, uterus and intestine. Skin 
hyperextsibility and joint hypermobility are 
minimal. The inheritance of classical, 
hypermobile and vascular type EDS is 
autosomal dominant. The kyphoscoliosis, 
dermatosparaxis and arthrochalasis types of 
EDS are relatively rare. The underlying 
genetic defects reside in collagen modifying 
enzymes lysyl hydroxylase (PLOD, 
kyphoscoliosis) and procollagen I N-terminal 
peptidase (dermatosparaxis) or in loss of 
functional protease cleavage sites in 
collagen type I caused by mutations in 
COL1A1 and COL1A2 (arthrochalasis) [60-
63]. 
 
ASSOCIATION OF TENASCIN-X WITH 
RECESSIVE EDS 
Burch et al. based their search for patients 
that might have disease caused by TNX on 
extensive prior work concerning the 
mechanism of disease in CAH. Specifically, 
it was well-known that 25% of CAH alleles 
carry deletions within the C4/CYP21/TNX 
locus that are usually inherited, but can 
arise de novo from unequal crossover 
events. In this model, there is misalignment 
of the 30 kb regions of homology in the A 
and B regions of the locus and 
recombination may occur anywhere in this 
region [64]. If recombination occurs between 
C4 genes, an allele is produced containing a 
hybrid C4A/B gene, normal CYP21B and 
TNX genes, and lacking CYP21A and XA. 
This allele does not produce overt disease 
because the remaining C4 gene, CYP21B 
and TNX genes are all functional, although 
reduced C4 gene dosage may be 
associated with autoimmune disease [65]. 
When recombination occurs between 
CYP21 genes, a hybrid CYP21A/B gene is 
produced. This allele is a CAH allele 
because the CYP21A/B hybrid will contain 
one or more truncating mutations found in 
the CYP21A pseudogene, while a normal 
TNX gene persists [66]. Many examples of 
these deleted C4 and CYP21 alleles exist, 
as well as the reciprocal triplicated alleles. 
Based on these findings, Burch et al. 
postulated that recombination also occurs 
between TNX and XA. Such a 
recombination event would be a CAH allele 
because CYP21B is deleted and should also 
alter function of the TNX gene if the 3’ end 
of XA (containing the 121 bp deletion) is 
retained. It was reasoned that such an allele 
might produce a contiguous gene syndrome 
consisting of CAH and a connective tissue 
disorder. A subsequent search identified 
such a patient: a 25-year-old man with salt-
wasting CAH and EDS consisting of 
hyperextensible skin and joints, 
accompanied by prominent bruising and 
absence of atrophic scarring [50]. The index 
patient was found to share the predicted 
hybrid TNX/XA allele with his father and a 
sister, both of whom were phenotypically 
normal. Further studies showed complete 
absence of TNX mRNA and protein in the 
proband. These studies were most 
consistent with a recessive pattern of 
inheritance, but no mutation was identified 
on the proband's maternal TNX allele and a 
complex interaction between CAH or its 
treatment and TNX haploinsufficiency was 
not formally excluded. 
In order to assess whether TNX 
deficiency independent of CAH is 
associated with EDS, a large number of 
patients needed to screened for TNX 
deficiency. To make this possible, 
Schalkwijk et al. developed a single dilution 
TNX ELISA. Screening was also facilitated 
by the observation that a 140 kDa C-
terminal fragment of TNX circulates in 
serum and its absence is uniformly 
associated with absence of TNX mRNA and 
protein in dermal fibroblasts. Serum from 
151 patients with isolated forms of EDS was 
screened and found 5 patients to be TNX-
deficient [67]. Absence of TNX mRNA and 
protein was confirmed in skin fibroblasts and 
all had clinical findings of classical Ehlers-
Danlos except that they had normal wound 
healing and lacked atrophic scars. Allele 
specific PCR demonstrated one patient (with 
CAH) was homozygous for the TNX deletion 
allele and another was heterozygous for the 
deletion. The remaining three patients 
carried homozygous inactivating mutations. 
This study confirmed the association of TNX 
deficiency with a recessive form of EDS and 
strongly suggested that TNX mutations were 
causative. 
The published clinical findings of all 
known patients with TNX-deficient EDS are 
summarized in table 1. While the number 
remains small [50;67;68], several 
generalizations about the clinical features 
can be made. The first is that all known 
affected individuals have both 
hyperextensible skin and hypermobile joints, 
and none have atrophic scars. In these 
patients, bruising has been a very prominent 
feature. Together, these features strongly 
suggest TNX deficiency and should trigger 
genetic evaluation and serum testing for 
TNX deficiency. Some female heterozygotes 
will have isolated joint hypermobility (see 
below), so these findings in an affected 
patient's mother or daughter do not exclude 
the diagnosis of recessive TNX-deficiency. 
Large joint dislocations are the most 
frequent debilitating finding in patients 
identified to date, although other important 
complications including mitral valve 
prolapse, chronic obstructive pulmonary 
disease, and diverticulosis have each been 
found in several patients and deserve 
enhanced surveillance in TNX-deficient 
EDS. Aortic root dilation or dissection 
haven’t been found in any TNX-deficient 
patient despite prominent expression of TNX 
in the adventitia of the normal aorta [58].  
 
ASSOCIATION OF TENASCIN-X WITH 
HYPERMOBILITY-TYPE EDS 
Following publication of these findings, 
Zweers et al. had the opportunity to examine 
many members of these families not 
originally available for study. Heterozygous 
deficient family members were found to 
have TNX levels 50% of those of normal 
individuals and 9 of 20 had isolated joint 
hypermobility, representing nearly two-thirds 
of heterozygous women in the families [69]. 
No male TNX heterozygous were affected. 
Zweers et al. then evaluated TNX levels by 
ELISA in 80 unrelated Dutch patients with 
hypermobility-type EDS and found six  
Table 1: Clinical findings in tenascin-X-deficient Ehlers-Danlos syndrome. 
 
Patient, reference Age (years), sex Skin/joint 
laxity 
Bruising Wound 
healing 
Other complications 
Index, Burch et al. 26, M ++/+++ +++ Slow, NL 
scar 
CAH, bronchiectasis, 
DJD 
 
 
I-a, Schalkwijk et al. 43, F ++/++ ++ NL Joint pain, striae 
 
 
I-b, Schalkwijk et al. 53, F +++/+ ++ NL Goiter 
 
 
II-a, Schalkwijk et al. 39, F ++/++ ++ NL Large joint dislocations, 
IgA deficiency 
 
 
II-b, Schalkwijk et al. 44, F ++/++ ++ NL Large joint dislocations 
COPD 
 
 
II-c, Schalkwijk et al. 43, M ++/++ ++ NL Hypertension 
 
 
III, Schalkwijk et al. 32, F ++/++ ++ NL CAH 
 
 
IV, Schalkwijk et al. 44, M ++/++ ++ NL Mitral prolapse/insuffic., 
large joint dislocations, 
GI bleeding 
 
 
V, Schalkwijk et al. 48, F ++/++ ++ NL Atherosclerosis 
 
 
VI, Lindor and Bristow 46, F +++/+++ +++ NL Rectal & uterine 
prolapse diverticulitis, 
COPD, mitral valve 
replacement 
 
 
VII, Lindor and Bristow 37, M +++/+++ + Slow, NL 
scar 
Diverticulitis, bowel 
perforation 
 
Abbreviations: CAH, congenital adrenal hyperplasia; DJD, degenerative joint disease; COPD, chronic obstructive 
pulmonary disease. 
 
 
individuals with TNX levels more than 2.5 
standard deviations below the mean, a 10-
fold excess over what might be expected by 
chance. Not unexpectedly, these patients 
had frequent joint subluxation and chronic 
arthralgias. Allele-specific PCR and 
sequencing of coding regions revealed two 
inactivating mutations in this group, 
supporting a causative role for TNX. The 
absence of coding-sequence mutations in 
the remaining four patients was surprising, 
but it was suggested that regardless of 
cause, the 50% reduction in TNX was likely 
to be responsible for disease. This study 
raised important questions of whether 
undefined TNX regulatory mutations might 
play an important role in this disorder. 
TENASCIN-X KO MOUSE MODEL 
Clinical studies of TNX deficient patients are 
limited in their scope due to ethical reasons 
and population size.  In order to study the 
aspects and effects of TNX deficiency on a 
variety of processes and tissues two groups 
independently generated TNX knockout 
(KO) mice [70;71]. Matsumoto et al.reported 
that the TNX KO mice were grossly normal 
but tumour growth and metastasis were 
increased compared to wildtype (WT) mice 
[71].  Mao et al. also reported that TNX KO 
mice are viable and grossly normal at birth, 
but by weaning, their skin was noticeably 
hyperextensible. Biomechanical testing 
confirmed increased deformability and 
reduced tensile strength of TNX KO skin 
compared to WT littermates. Ultrastructural 
examination showed relatively normal size 
and shape of collagen fibrils, but the density 
of fibrils in dermis was significantly reduced, 
leading to a 30% reduction in collagen 
content in skin. TNX KO skin fibroblasts 
were studied in cell culture and found to 
have near normal collagen synthesis, but a 
significant deficit in the amount of collagen 
deposited into insoluble matrix. This led Mao 
et al. to the hypothesis that TNX-deficiency 
causes EDS not by interfering with collagen 
synthesis or processing, as has been 
described in other forms, but rather through 
regulation of fibril deposition into matrix by 
dermal fibroblasts [70].  
 While the skin phenotype of the TNX 
KO mouse was investigated, mobility of the 
joints was not investigated. Mouse models 
for joint laxity have been described 
previously for lumican- and fibromodulin 
deficient mice, which show a decrease in 
tendon stiffness and integrity. Furthermore 
mice that lack thrombospondin 2 have 
increased flexibility in tail tendons and 
ligaments, which permits tying a knot in the 
tail.  This manipulation is not possible in WT 
mice. Abnormalities in these mice models 
have been associated with abnormal 
collagen fibrillogenesis [72;73]. 
It has long been known that collagen 
is deposited into widely varying tissue-
specific forms, and while recent studies 
confirm that this process is highly regulated 
in fibroblasts, the molecular details of this 
process are not yet completely understood 
[9;10;74]. Mao et al. postulated that TNX 
participates in this pathway, and proposed 
that other genes playing a role in this 
process may be responsible for other 
Ehlers-Danlos variants [52]. 
 
TENASCIN-X AND THE COLLAGEN 
FIBRIL 
Recently, several models have been 
proposed for TNX to interact with collagen 
fibrils. Bristow et al. proposed a model in 
which TNX might regulate the spacing 
between fibrils, and contribute to strength of 
the dermis, through direct binding to 
collagen fibrils [75]. Bristow et al. stated that 
several lines of evidence support this 
concept. First, Lethias et al. [76] cloned 
bovine TNX as a fibril-associated protein in 
dermal collagen preparations. Second, 
recent studies suggest that native TNX 
binds collagen and the native protein 
increased both the rate and extent of fibril 
formation in vitro [77]. Third, Lethias showed 
that the 10th and 11th fibronectin repeats of 
TNX interact with the dermatan sulfate 
chains of decorin, a small leucine-rich 
proteoglycan that binds collagen avidly and 
regulates fibrillogenesis [78;79]. Finally, 
immunogold labeling localizes TNX to the 
fibril surface in human dermis, while staining 
is absent from TNX-deficient skin [75]. 
Together these data strongly support 
physical interaction between TNX and 
collagen fibrils. However, if TNX specifically 
regulates inter-fibrillar distance, the protein 
must interact directly or indirectly with 
multiple fibrils. The simplest way for this to 
occur is if TNX is multimer. This is the case 
for both TNC and TNR and sequences at 
the N-terminus of these molecules that 
mediate oligomerization are conserved in 
TNX [39;41;80]. However, multimeric TNX 
complexes in extracts of tissue or fibroblast 
conditioned medium have not been 
demonstrated. Veit et al. demonstrated 
binding of TNX to collagen type XII and 
proposed a model in which collagen XII 
interacts with TNX, both bound to fibrils by 
decorin thus linking collagen fibers together 
[81]. Following this report Lethias et al. 
demonstrated by rotary shadowing that 
recombinant TNX could form trimers. 
Furthermore they showed binding to several 
types of fibrillar and FACIT collagens, 
however trimerisation did not appear 
essential for binding as monomeric TNX 
extracted from bovine tissue exhibited the 
same binding properties [82]. 
 
TENASCIN-X, ELASTOGENESIS, AND 
MATRIX REMODELING 
Zweers et al. [83] followed up molecular 
observations on TNX-deficient patients with 
ultrastructural analysis of their skin. They 
were able to confirm normal appearing fibrils 
and reduced collagen content, but also 
noticed irregular and immature elastin fibers 
containing few or no microfibrils. Elastin 
staining showed fragmentation and reduced 
branching of fine elastic fibers in papillary 
dermis and fragmented or clumped coarse 
elastic fibers in reticular dermis. Generalized 
elastic fiber abnormalities have not been 
shown in other forms of EDS, so it seems 
likely that the elastic fiber abnormalities are 
a direct result of TNX-deficiency and not a 
secondary consequence of altered collagen 
metabolism. What is still unclear is the 
extent to which the TNX-deficient phenotype 
is altered by co-existing elastin 
abnormalities. 
Bristow et al. performed a 
microarray-based analysis of expression 
differences between TNX KO and WT 
mouse fibroblasts that may shed light in this 
phenomenon. They found significant up-
regulation of fibrillin-2 and stromelysin-3 [M. 
Collier and J. Bristow, unpublished]. 
Stromelysin-3 is a protease whose primary 
known target is the α-1 proteinase inhibitor 
that in turn, normally binds and inhibits 
elastase [84]. The net consequence of these 
alterations may be activation of dermal 
elastic fiber remodeling that could account 
for the observed changes in vivo. 
Recently reports of additional matrix 
alterations in TNX KO mice have emerged. 
Matsumoto et al. have reported adhesive 
defects in TNX KO fibroblasts, accumulation 
of triglycerides and altered expression of 
collagen VI, matrix metalloproteases 2 and 9 
and altered composition of triglyceride 
associated fatty acids in independently 
derived TNX KO mice [71;85-89]. While the 
implications of these findings for TNX-
deficient EDS are uncertain, these 
observations together suggest that TNX has 
effects on matrix synthesis and remodelling 
that extend beyond the fibrillar collagens. 
 
AIMS OF THIS THESIS 
Before the start of this project, Burch et al. 
[50] and Schalkwijk et al. [67] described 
clinical and genetic findings in a number of 
TNX-deficient patients and showed TNX 
deficiency causes a recessive form of EDS. 
Schalkwijk et al. [67] showed that a 140 kDa 
TNX species is present in serum and 
developed a sandwich ELISA to 
conveniently screen sera for TNX deficient 
patients. Mao et al. [70] generated a TNX 
KO mouse model and described an 
alteration in collagen deposition and fragile 
skin phenotype. However, how the absence 
of TNX resulted in the observed phenotypes 
remained unclear. The work described in 
this thesis was specifically aimed at 
answering the following questions: 
 
1. Is TNX involved in the initial 
deposition of ECM components or in 
maturation and stability of the ECM?  
 
2. Do TNX deficient mice exhibit joint 
hypermobility and if yes, which 
morphological changes are 
associated with increased mobility? 
 
3. What are the interaction partners of 
TNX in the ECM and how does 
absence of TNX influence their 
deposition, maturation and stability? 
 
4. Does TNX deficiency cause 
pathological conditions associated in 
humans other than skin laxity and 
joint hypermobility? 
 
5. Which TNX fragments can be found 
in human serum and are they 
biological active?  
In chapters 2 (skin development), 3 (skin 
wound healing) and 4 (uterus remodeling) 
the role of TNX in deposition, maturation 
and stability of ECM components (aim #1) 
was investigated. Joint mobility of mice is 
investigated in chapter 2 (aim #2).  
Biochemical evaluation of interaction 
partners of TNX is described in chapters 5 
(fibrillar collagens and elastin), 6 (collagen 
type XII) and 7 (serum TNX), while the effect 
of TNX deficiency on these interaction 
partners was investigated in chapters 2, 3 
and 4 (aim #3). Chapter 3 and 4 describe 
the effect of TNX deficiency in patients on 
wound healing, pregnancy and uterus tissue 
stability (aim #4). Finally, TNX species 
present in human serum were investigated 
in chapter 7 (aim #5). 
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Abstract Deficiency of the extracellular matrix protein
tenascin-X (TNX) causes a recessive form of Ehlers–
Danlos syndrome (EDS) characterized by hyperextensible
skin and hypermobile joints. It is not known whether the
observed alterations of dermal collagen fibrils and elastic
fibers in these patients are caused by disturbed assembly
and deposition or by altered stability and turnover. We used
biophysical measurements and immunofluorescence to
study connective tissue properties in TNX knockout and
wild-type mice. We found that TNX knockout mice, even at
a young age, have greatly disturbed biomechanical proper-
ties of the skin. No joint abnormalities were noted at any
age. The spatio-temporal expression of TNX during normal
mouse skin development, during embryonic days 13–19
(E13–E19), was distinct from tropoelastin and the dermal
fibrillar collagens type I, III, and V. Our data show that TNX
is not involved in the earliest phase (E10–E14) of the
deposition of collagen fibrils and elastic fibers during fetal
development. From E15 to E19, TNX starts partially to
colocalize with the dermal collagens and elastin, and in
adult mice, TNX is present in the entire dermis. In adult
TNX knockout mice, we observed an apparent increase of
elastin. We conclude that TNX knockout mice only par-
tially recapitulate the phenotype of TNX-deficient EDS
patients, and that TNX could potentially be involved in
maturation and/or maintenance of the dermal collagen and
elastin network.
Keywords Tenascin-X . Collagen . Elastin .
Development . Ehlers‐Danlos syndrome . Mouse (TNX
knockout)
Introduction
TNX is a large extracellular matrix glycoprotein (Bristow et
al. 1993; Lethias et al. 1996; Elefteriou et al. 1997; Ikuta et
al. 1998) that is expressed in a variety of tissues including
skin, joints, heart, and blood vessels. Complete deficiency
of TNX in humans leads to a recessive form of Ehlers-
Danlos syndrome (EDS), and TNX haploinsufficiency is a
cause of hypermobility type EDS (Burch et al. 1997;
Schalkwijk et al. 2001; Zweers et al. 2003). Adult TNX-
deficient patients show abnormal elastic fibers and reduced
collagen deposition in skin (Zweers et al. 2004). We have
recently found that a high serum TNX concentration is a
risk indicator for abdominal aorta aneurysm (Zweers et al.
2005). TNX-deficient patients appear to have normal vessel
wall compliance and distensibility of the large arteries;
however, two out of nine described patients underwent
surgery for mitral valve replacement (Peeters et al. 2004;
Lindor and Bristow 2005).
Two groups have independently generated TNX knockout
mice (Matsumoto et al. 2001; Mao et al. 2002). Mao et al.
(2002) have shown that TNX knockout mice mimic EDS
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through alterations in collagen deposition, as seen in TNX-
deficient patients. Matsumoto et al. (2004a–c) have demon-
strated altered fatty acid composition in TNX knockout mice
compared with wild-type mice and increased MMP2
activation. The same group have found that tumour invasion
and metastasis are enhanced in TNX knockout mice
(Matsumoto et al. 2001, 2002). The enhanced tumor in-
vasion found in TNX knockout mice is supported by the data
on cutaneous malignant melanoma in MeLiM swine. These
melanoma cells show a dramatic downregulation of TNX,
which could account in part for the invasive phenotype of
this tumor (Geffrotin et al. 2000).
In our previous study of the dermal abnormalities of five
adult TNX index patients (Schalkwijk et al. 2001), we could
not determine whether these alterations were attributable to
developmental defects in the collagen and elastic fibre
network, or to post-natal instability or breakdown. Here, we
have investigated TNX expression in wild-type and TNX
knockout mice during fetal skin development in relation to
the expression of fibrillar collagens type I, III, and V and
elastin. Our results indicate that the TNX knockout mouse is
a suitable model for skin fragility but not for joint hyper-
mobility. The reduced biomechanical strength of the skin in
adult TNX knockout mice can be found in juvenile mice but
is unlikely to be caused in the initial phase of deposition of
the collagenous and elastic fibre network.
Materials and methods
Test animals
TNX knockout mice were obtained as described previously
(Mao et al. 2002). For all studies, except for measurements
of the medial collateral ligament (MCL), we used +/+, +/–,
and –/– offspring from heterozygous parents obtained by
the backcrossing of TNX knockout mice with four
generations of C57/BL6 mice. For optical coherence
tomography and measurements of the stiffness of the
MCL, littermates (3–6 months old) were used from TNX
heterozygous parents obtained by backcrossing with two
generations of C57/BL6 mice. The number of mice for
each test is indicated in the results. The experimental
design was approved by the animal use committee of
Radboud University, Nijmegen.
Processing of samples
At each time point, adult mice were killed in a sealed
compartment by exposure to a mixture of carbogen gas and
increasing concentrations of CO2. Mouse fetuses were killed
by decapitation. Complete hind legs of mice were stored
at –20°C prior to measurements of the MCL and were
processed as previously described (Gijssen et al. 2004). Skin
samples for paraffin sections were fixed in buffered forma-
lin for 4 h. Skin samples for frozen sections were embedded
in Tissue–Tek O.C.T. compound (Sakura Finetek Europe,
The Netherlands) and snap-frozen in liquid nitrogen. The
breaking strength of mouse skin samples was measured
immediately after the animals had been killed.
Histochemistry and immunohistochemistry
Staining of elastic fibers was performed by a modified
Hart’s method on paraffin sections (7 μm thick; Starcher et
al. 2005). Paraffin and frozen sections (7 μm thick) were
stained with antibodies against TNX, tropoelastin (TE), and
collagens type I, III, and V. Detection was performed with
antibodies conjugated to fluorescein isothiocyanate (FITC,
green) and Alexa Fluor 594 (AF594, red; Table 1). Cell
nuclei were counterstained with 4,6-diamidino-2-phenylin-
dole (DAPI; Molecular Probes, The Netherlands; blue).
Computational analysis of (tropo) elastin and elastic
fiber density
Each micrograph was analyzed by using IPlab software
(Scanalytics, US). Once a representative “region of inter-
est” (ROI), excluding hair follicles, had been chosen, all
positive segments in the ROI were marked with a specific
color. The surface of the colored area was divided by the
ROI surface to determine the signal density.
Measurement of the stiffness of the MCL
The stiffness of the MCL was determined as previously
described (Gijssen et al. 2004). Briefly, the tibia and femur
of the mouse leg were clamped in a tensile tester. All tissues
were removed from the femur and tibia with the exception
of the MCL. Forces were applied in the longitudinal
direction of the tibia and MCL.
Measurement of the cross-sectional area of the MCL
by optical coherence tomography
Optical coherence tomography, which is the optical equiv-
alent of ultasound imaging, is a noninvasive cross-sectional
imaging technique for biological systems (Huang et al.
1991). For the imaging of the MCL, a reference point was
visually determined at approximately the midpoint of the
ligament, in between the tibia and femoral insertion
(approximately 1 mm distal to the joint cavity). Images
were taken from 2 mm distal to 2 mm proximal to the
reference point to cover the full length of the MCL
(approximately 3.5 mm). Cross-sectional images (β-scans)
were made at 0.2-mm intervals to obtain a series of 21 β-
scans along the full length of the ligament. The cross-
sectional area of aMCLwas calculated with custom analysis
software written in Labview 7 (National Instruments, US) by
using β-scans 8–15 in which the MCL was clearly visible
and of constant dimensions. Optical coherence tomography
has been previously validated for ligaments and tendons
(Martin et al. 2003).
Flexibility of the tail
Increased flexibility of tail ligaments and tendons, as de-
scribed for the TSP2-null mouse (Kyriakides et al. 1998),
was ascertained for the TNX knockout mouse. In a blind
randomized test, the animals were maintained under anes-
thesia at an isofluran dose of 2.5%–3.0% in a N2O2 gas
mixture (50%–65% O2) while the investigator attempted to
tie a knot in the mouse tail.
Breaking strength
A rectangular strip of dorsal skin (7 mm × 3.5 cm) was
prepared from the killed mice by using a custom-made
apparatus. The skin segment was clamped in a device that
exerted a continuously increasing force in a longitudinal
direction. The breaking strength was defined as the peak
force necessary to induce tearing of a tissue segment and
was expressed in grams (1000 g is equivalent to 9.281 N),
as described previously (Waard de et al. 1995).
Biochemical analysis of hydroxyproline
and desmosine content
Desmosine analysis of mouse skin samples was used to
measure the elastin content of the skin. After removal of the
hair, a 3-mm biopsy punch was obtained from the caudal
dorsal skin of themice and placed in a secure-lockmicrofuge
tube. The sample was hydrolyzed in 500 μl 6 N HCl at
105°C for 24 h. The hydrolysate was evaporated to dryness,
re-dissolved in 200 μl water, and microfuged to remove
insoluble material. A 20-μl aliquot was removed for des-
mosine analysis by radioimmunoassay (Starcher and Conrad
1995), and 1 μl was used for protein determination by a
ninhydrin-based assay as described previously (Starcher
2001). Hydroxyproline (OHP) analysis was used as a
method for measuring the collagen content of the skin.
The OHP content was determined by amino acid analysis
from the same hydrolysate as the desmosine analysis.
Results
Biomechanical properties of skin and joints in TNX
knockout and wild-type mice
Littermates –/–, –/+, and +/+ for TNX were used to
measure skin and joint biomechanical properties. Figure 1
shows the applied force required for skin failure (breaking
strength). The breaking strength of TNX knockout mouse
skin was significantly lower than that of heterozygous or
wild-type littermates. The phenotype was appreciable even
at the earliest possible age that could be investigated (2
weeks neonatal), and the difference in skin strength
between wild-type and TNX knockout mice increased
with age (Fig. 1). Wild-type and heterozygous mice did not
significantly differ. To investigate joint laxity in these
animals, we performed two tests. First, we tested whether
Fig. 1 Breaking strength of mouse skin. TNX knockout mice (KO)
have weaker skin compared with that of heterozygous (HET) and wild-
type (WT) littermates. The difference is appreciable even at a young age
and increases over time (for comparisons of adult mice of 3–6 months
of age, n=12 for knockout, n=6 for heterozygous, and n=5 for wild-
type mice; for mice of 2 weeks of age, n=6 for knockout, n=8 for
heterozygous, and n=10 for wild-type mice). For all comparisons to
wild-type mouse, *P<0.001 when compared with knockout mice
(+ not significant when compared with heterozygous mice)
Table 1 Antibodies used for immunofluorescence studies
ECM constituents Primary antibody mixture Secondary antibody mixture
Elastin and TNX Goat polyclonal anti-rat (tropo)elastina Chick polyclonal anti-goat AF594f
Guinea pig anti-human TNXb Rabbit polyclonal anti-guinea pig FITCg
Collagens type I and TNX Goat polyclonal anti-human collagen Ic Chick polyclonal anti-goat AF594f
Guinea pig anti-human TNXb Rabbit polyclonal anti-guinea pig FITCg
Collagen type III and TNX Goat polyclonal anti-human collagen IIId Chick polyclonal anti-goat AF594f
Guinea pig anti-human TNXb Rabbit polyclonal anti-guinea pig FITCg
Collagen type V and TNX Goat polyclonal anti-human collagen Ve Chick polyclonal anti-goat AF594f
Guinea pig anti-human TNXb Rabbit polyclonal anti-guinea pig FITCg
aElastin Products, USA
bSchalkwijk et al. 2001
cSouthernBiotech, USA
dSouthernBiotech, USA
eSouthernBiotech, USA
fMolecular Probes, The Netherlands
gDakocytomation, Denmark
the laxity of the tail ligaments of the –/– mice was such to
permit tying a knot in the tail; this is not possible in wild-
type mice but has been described for the thrombospondin-2
knockout mouse (Kyriakides et al. 1998). We found,
however, that this manipulation was not possible in the
TNX–/– mouse (not shown). Secondly, as a measure for
joint hypermobility, the stiffness of the MCL in the knee
joint was analyzed. As shown in Table 2, our measure-
ments did not reveal a difference in ligament stiffness
between TNX knockout mice and wild-type littermates. In
order to exclude the possibility of a thicker MCL in TNX
knockout mice as a compensatory mechanism, we mea-
sured the mean thickness of the ligament by optical
coherence tomography. The MCL thickness in TNX
knockout mice did not significantly differ from wild-type
littermates (Table 2). Histological analysis of wild-type and
TNX knockout ligaments revealed no obvious differences
(data not shown).
Fig. 2 TNX immunofluorescent
staining of the developing skin of
wild-type mice. a At stage E14,
no significant signal in the pro-
spective dermis is detected (blue
nuclear staining with DAPI).
b By stage E15, TNX expression
(green) is visible in the develop-
ing reticular dermis and around
the fascia of the carnosus muscle
layer. c, eAt E18 and in 1-day-old
neonatal mice, respectively, ex-
pression of TNX has extended
further into the dermis. d Higher
magnification of the rectangle in
c; TNX is expressed in the fetal
mouse in a distinct fibre-like
pattern. f In adult mouse skin,
TNX is observed throughout the
dermis in a more homogeneous
pattern. g Higher magnification
of the rectangle in f. h The
specificity of the anti-TNX serum
is demonstrated in TNX knock-
out mice skin (E18), which is
devoid of signal. Bars 50 μm
(a–c, e, f, h), 25 μm (d, g)
Table 2 Biomechanical properties of the MCL of TNX knockout
and wild-type littermates. The MCL of TNX knockout and wild-
type littermates were the same in thickness and stiffness (for all
comparisons, + not significant)
Character Genotype Mean SD n
Stiffness of MCL (N/mm) Wild-type 5.08+ 1.12 8
TNX knockout 4.96 1.50 7
Cross-sectional area MCL (mm2) Wild-type 0.058+ 0.008 8
TNX knockout 0.052 0.010 5
Expression of TNX in fetal and adult mouse skin
Sections of fetal, viz., embryonic day 13–20 (E13–E20),
and adult skin were immunostained to reveal the expres-
sion of TNX at various developmental stages. The
epidermis was devoid of signal at all stages, except for
occasional non-specific staining of the stratum corneum. At
E14, no significant signal was detected in the prospective
dermis (Fig. 2a). From stage E15 onward, TNX expression
was found in the lower dermis and around the fascia
surrounding the panniculus carnosus beneath the develop-
ing dermis (Fig. 2b). TNX expression extended toward the
Fig. 3 Merged micrographs showing immunofluorescent double-
staining for TNX (green) and collagens (red) type I (a, d, g, j,m), III
(b, e, h, k, n), or V (c, f, i, l, o) in developing skin of wild-type mice.
Nuclei are stained blue with DAPI. The different types of collagen
are expressed even at fetal stages E10 (a–c) and E14 (d–f) in the
prospective dermis. At E18 (g–i) and 1-day-old neonatal (1 day
Neo.) mice (j–l), TNX starts to colocalize with the various types of
collagens (orange, yellow). In adult mice, TNX is expressed in the
entire dermis and overlaps with collagens type I (m), III (n), and V
(o). Non-specific staining of the stratum corneum was present in
some sections. Bars 50 μm
upper part of the developing dermis at E18 and neonatal
stages (Fig. 2c,e) and appeared in a fibre-like pattern (E18,
Fig. 2d). In the adult mouse (Fig. 2f), the distinct fibre-like
pattern was less clear, and the entire dermis exhibited a
strong diffuse pattern (Fig. 2g). The specifity of our anti-
TNX serum is illustrated in Fig. 2h, which shows the
complete absence of staining at the E18 stage of a TNX
knockout mice.
Differences in spatio-temporal appearance of TNX
and the dermal fibrillar collagens
To address the question of whether TNX is involved in the
assembly of collagen fibrils during normal dermal differ-
entiation, we examined the appearance of collagens type I,
III, and V in comparison with TNX. Collagens type I, III,
and V were weakly present on E10 (Fig. 3a–c) in the
undifferentiated dermal mesenchyme beneath the periderm
of normal mouse fetuses (red signal). Expression of these
collagens was abundant at E14 (Fig. 3d–f) before the start
of TNX expression. The fibre-associated expression pat-
tern of TNX, however, overlapped with the collagen
network in the reticular dermis (orange signal) and around
the fascia of the panniculus carnosus (orange and yellow
signals), as shown in the overlays of the immunofluo-
rescent stainings from E18 and 1-day-old neonatal mice
(Fig. 3g–l). In the papillary dermis, the various collagen
types were stained red, and TNX expression had not yet
started in this compartment (Fig. 3g–l). In adult mice, TNX
was expressed diffusely throughout the dermis and over-
lapped with collagens type I, III, and V, which were also
expressed throughout the dermis (orange and yellow
signals; Fig. 3m–o). No obvious differences in expression
of the various collagen types and TNX were noted between
TNX knockout and wild-type mice during development
(data not shown).
Previous studies in mouse and human have shown that
collagen content is reduced in adult skin of TNX-deficient
individuals (Mao et al. 2002; Schalkwijk et al. 2001).
Because immunofluorescent staining of dermal collagens
could not be used to quantify collagen content, we
performed an analysis of OHP content in TNX knockout
and wild-type mouse skin. We found a slight reduction in
collagen content, but this was not as prominent as in
previous studies (Table 3).
Differences in spatio-temporal appearance
of TNX and elastin
To address the question of whether TNX is involved in the
assembly of elastic fibers during dermal differentiation, we
used an antibody directed against TE as a marker for
developing elastic fibers. A thin discontinuous layer of TE
expression was present even in the undifferentiated dermal
mesenchyme at E10 (red staining in Fig. 4a). Thereafter,
TE staining was strong and continuous in the fascia lining
the developing muscle cells of the panniculus carnosus. At
E18, many TE-positive fibers were found in the outer layer
of the fascia and scattered throughout the prospective
reticular dermis as witnessed by the orange-yellow staining
in merged double-staining images (Fig. 4b). Clearly, TNX
expression differed temporally and spatially from TE
expression in the developing mouse skin. However, from
E15 onward, TNX started partially to colocalize with
elastin. The TNX fibre-like pattern found at this stage
overlapped with the pattern of TE-positive fibers around
the fascia of the panniculus carnosus and in the prospective
reticular dermis (Fig. 4b). In adult mouse skin, TNX was
present diffusely throughout the entire dermis and therefore
by definition overlaps with TE staining (Fig. 4c).
Fig. 4 Merged micrographs of immunofluorescent double-staining
for TNX (green) and tropoelastin (TE; red) in developing skin in
wild-type mice. TE is expressed in the undifferentiated mesenchyme
at the earliest investigated stage, E10 (a). The signals for TE and
TNX partially overlap (orange, yellow) in the developing mice skin
around the fascia of the carnosus muscle at E18 (b). In adult mice
(c), the entire dermis is stained positively for TNX with overlapping
signal for TE (orange, yellow). Bars 50 μm
Table 3 Hydroxyproline (OHP) content in skin of adult (8–9months
old) mice as a measure for total collagen (+P=0.09, ++P=0.07)
Amount OHP Genotype Mean SD n
Content in nmol per mg
protein
Wild-type 281.4+ 42.7 7
TNX knockout 253.8 38.9 10
Content in nmol per mm2
skin
Wild-type 31.6++ 10.4 7
TNX knockout 24.7 8.3 10
Difference in TE expression in knockout mice
compared with heterozygous and wild-type mice
In adult TNX-deficient EDS patients, we have previously
observed the fragmentation and clumping of elastic fibers
(Zweers et al. 2004). We therefore examined the appear-
ance of elastic fibers in adult knockout mice compared with
heterozygous and wild-type mice by using immunofluo-
rescent staining for TE. We did not observe obvious
differences in the morphology or spatial distribution of the
TE-positive elastic fibers, although the difference in
density of the fibers was appreciable between adult wild-
type and TNX knockout mice. Image analysis followed by
computational quantitation showed that the signal intensity
for TE was significantly higher in TNX knockout (Fig. 5c)
mice than in heterozygous (Fig. 5b) and wild-type (Fig. 5a)
littermates. The difference in density appeared at 3–6
months of age (Fig. 5e). Wild-type and heterozygous mice
did not significantly differ in signal intensity. We sub-
sequently investigated whether the differences in density
of TE-positive fibers were reflected in the density of
mature elastic fibers as determined histochemically by
Fig. 5 Analysis of elastin and elastic fibers. Immunostaining for TE
on paraffin sections of 9-month-old mice (a–c). At 3–6 months,
TNX knockout mice (c) show a higher density of TE in their dermis
than do wild-type (a) and heterozygous (b) mice (represented
graphically in e). The density of mature elastic fibers made visible
by modified Hart’s staining in TNX knockout skin (not shown)
compared with wild-type mice (d) is increased (f). No differences in
desmosine content expressed per milligram protein (h) or per mm2
(g) skin were found between the different phenotypes in adult mice.
*P<0.01, **P<0.05, + not significant. For all comparisons, n=12 for
each genotype for mice at 3–6 months, n=6 (or more) for mice at
2 weeks and 9 months. For 2-month-old mice, n=8 for heterozygous
mice, n=4 for TNX knockout mice and n=3 for wild-type mice (KO
knockout, WT wild-type, +/− heterozygous)
modified Hart’s staining (shown for wild-type in Fig. 5d).
Although the differences between wild-type and TNX
knockout mice were not as obvious as for the TE
immunostaining, computational analysis showed a signif-
icant difference in the densities of mature elastic fibers
between TNX knockout and wild-type mice (Fig. 5f). To
investigate these differences between wild-type and knock-
out mice further, we measured the amount of desmosine, a
tetrafunctional crosslink specific for elastin, in mouse skin.
Desmosine content did not differ between wild-type and
knockout mice, irrespective of whether it was expressed
per milligram protein or per skin surface area (Fig. 5g,h).
Discussion
The aim of our investigations was to provide a detailed study
of TNX expression in skin and to examine the consequences
of TNX deficiency at the functional and morphological
levels. We have found no obvious differences in tail mobility
and MCL stiffness, which we have used as a measure for
joint hypermobility, between wild-type and knockout mice.
We conclude that TNX knockout mice show a similar skin
phenotype as human TNX-deficient patients but that these
mice are not a suitable model to investigate joint hyper-
mobility. On the basis of colocalization studies, we surmise
that TNX is more likely to be involved in the maturation and
maintenance of the collagen and elastin network than in its
initial deposition.
TNXexpression has not yet been studied in depth during the
development of the skin. Geffrotin et al. (1995) have reported
TNX transcripts in 87-day-old pig fetuses. Matsumoto et al.
(1994) have demonstrated TNX transcripts in mice at E17 and
staining of the dermis, but this is less strong toward the dermis
at E15.5. This is in accordancewith our data. However, no data
from other fetal stages have been published, and TNX
expression has not been studied at the protein level. We show
that expression starts at E15 and progresses from the reticular
dermis toward the papillary dermis during development. TNX
is expressed in a fiber-like network during development, but
this network is lost in adulthood. This suggests a possible
difference in function for TNX during the development of skin
and in mature skin.
We suggest that TNX is not involved in the initial de-
position of collagen fibrils or elastic fibers because expres-
sion of the dermal fibrillar collagens and expression of TE
starts well before TNX is expressed in the dermis. However,
during development, the characteristic fiber-like pattern of
TNX colocalizes with the collagens type I, III, and V
networks; this is in accordance with previously results
showing that TNX colocalizes with banded collagen fibrils
in bovine fetal skin (Lethias et al. 1996; Elefteriou et al.
1997). The expression of the various types of fibrillar
collagens in developing mouse skin has not been compre-
hensively studied in detail at the protein level. Van Exan and
Hardy (1984) have found that fibrils are present at the earliest
of investigated fetal stages (E12), and Niederreither et al.
(1995) have demonstrated, by using in situ hybridization,
that collagens type I and III are expressed in dermatomes at
E10.5 and E12.5 in the presumptive dermis of whole mouse
fetuses. The expression of collagen type Vappears to mimic
that of collagen type I, and transcripts are localized to dermal
cells (Garrone et al. 1997; Andrikopoulos et al. 1992). These
data are in accordance with our findings at the protein level.
A reduction in collagen occurs in the skin of adult TNX
knockout mice (Mao et al. 2002) similar to that in TNX-
deficient patients (Zweers et al. 2004). Although we have
found a small difference in OHP content between TNX
knockout and wild-type mice, the differences are not as
profound as observed by Mao et al. (2002). Of note, the
TNX null allele used in our study is on a different
(homogenous C57Black6) background than that used by
Mao et al. (2002). Together with the reduction of collagen,
Mao et al. (2002) have found a decrease in the stress-strain
properties of adult TNX knockout mice. We have confirmed
this alteration of skin biomechanical properties in a test of
skin breaking strength. We have found that, even at the
youngest possible investigated age (2-week-old mice), skin
strength is severely disturbed. Although no gross abnor-
malities of the collagen fibrils have been observed, a minor
increase in size variation has been reported (Mao et al.
2002). Moreover, Minamitani et al. (2004) have found an
increase in thickness of collagen fibrils in 3-month-old mice.
Differences in skin mechanical properties between wild-
type and TNX knockout are probably not solely caused by
differences in the collagen density of the skin; qualitative
differences in, for example, crosslinking and interaction
between collagen fibrils might also play a role.
In TNX-deficient patients, we have previously observed
altered elastic fibers in sections stained by Elastica von
Gieson stain (Zweers et al. 2004). This stain appears ill-
suited for the visualization of fetal and neonatal elastic
fibers in mice. We have instead used a TE antibody, which
recognizes both soluble TE and cross-linked elastin. In
addition, we have used modified Hart’s stain, a histochem-
ical stain suitable for the visualization of elastic fibers in
mouse skin. Immunofluorescence on paraffin sections has
revealed an increased density of TE/elastin in TNX
knockout mice compared with heterozygous TNX and
wild-type mice at 3–6 months of age. This difference in
density for TE/elastin is reflected, although less promi-
nently, in mature elastic fibers in the dermis detected by
modified Hart’s staining. The quantification of desmosine
content, however, has revealed no significant differences,
suggesting a lower amount of desmosine crosslinks per
elastic fiber in TNX knockout mice, which might possibly
lead to less stable elastic fibers. This could in turn lead to
increased synthesis as a possible compensatory mecha-
nism. The elastic fibers of the TNX knockout mice might
also be more susceptible to breakdown, since the differ-
ences in TE/elastin density appear in adulthood, in which
case the TE/elastin might pick up elastin breakdown
products from elastic fibers. Once again, the TNX knock-
out mice might compensate for this by (over) producing
new elastic fibers, but this awaits further investigation. The
elastic fiber phenotype in the TNX knockout mice does not
resemble the phenotype found in humans. The organization
and cellular source of elastic fibers in mice is known to
differ from those in humans (Starcher et al. 1999, 2005).
Both in humans and in mice, TNX appears to be involved
in the maintenance of normal elastic fibers. However, TNX
does not seem to be associated with the initial deposition of
TE/elastin, as immureactivity to the TE antibody is de-
tected in the dermis before TNX expression starts. TNX
could nevertheless be involved in the maturation of elastic
fibers, since mature elastic fibers only start to appear
approximately 5 days post partum in mice, coinciding with
the start of hair growth (Starcher et al. 2005).
The morphological and biochemical abnormalities in
TNX-deficient skin are mild compared with the strongly
disturbed biomechanical properties. This suggests that
TNX exerts more subtle functions that contribute to
connective tissue stability. Studies by others have pre-
viously indicated that TNX interacts with various other
matrix molecules (Elefteriou et al. 1997, 1999, 2001; Ikuta
et al. 2000; Lethias et al. 2001; Matsumoto et al. 1994;
Minamitani et al. 2004). Obviously, the biomechanical
properties of the matrix will be affected by these
interactions, and this is clearly an area of future research.
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CHAPTER 3 
 
WOUND HEALING IN TENASCIN-X DEFICIENT MICE 
SUGGESTS THAT TENASCIN-X IS INVOLVED IN MATRIX 
MATURATION RATHER THAN MATRIX DEPOSITION 
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ABSTRACT 
Tenascin-X (TNX) is a large, multi-domain, 
extracellular matrix (ECM) glycoprotein. 
Complete deficiency of TNX in humans 
leads to a recessive form of Ehlers-Danlos 
syndrome (EDS) and TNX 
haploinsufficiency is a cause of 
hypermobility type EDS. EDS patients 
appear to have a higher risk for several 
complications during pregnancy such as 
pelvic instability, premature rupture of 
membranes and postpartum hemorrhage. 
Here we present a study on genitourinary 
and obstetric complications in TNX-
deficient women of reproductive age. We 
found several complications that are in line 
with previous findings as observed in other 
EDS types. In TNX knockout (KO) mice, 
we found mild pregnancy-related 
abnormalities. Morphological and 
immunohistological analysis of uterine 
tissues did not reveal obvious quantitative 
or spatial differences between TNX KO 
and wildtype (WT) mice with respect to 
collagen types I, III, V and XII or elastic 
fibers. We conclude that TNX deficiency 
leads to impaired biomechanical 
properties of the connective tissue, such 
as laxity of the vaginal wall, uterus or 
ligaments, leading to an increased risk for 
obstetric complications. 
 
INTRODUCTION 
Tenascin-X (TNX) is a large, multi-domain, 
extracellular matrix (ECM) glycoprotein 
composed of EGF like-repeats, fibronectin 
type III repeats and a C-terminal fibrinogen 
domain [1-5]. Complete deficiency of TNX 
in humans leads to a rare recessive form 
of Ehlers-Danlos Syndrome (EDS) and 
TNX haploinsufficiency is a cause of 
hypermobility type EDS. Patients of both 
EDS types exhibit mild to severe joint 
hypermobility. The skin of TNX-deficient 
patients is markedly lax with poor recoil 
properties and shows easy bruising. The 
collagen density appears reduced in the 
dermis of these patients and the elastic 
fibers are abnormal [6-10]. Most literature 
concerning pregnancy in EDS uses the old 
classification of nine subgroups. In our 
study, we use the revised classification of 
six subtypes of EDS [11]. Tissue fragility is 
a hallmark of EDS and is present in all 
different subtypes. EDS patients appear to 
have a higher risk of several complications 
during pregnancy such as pelvic instability, 
premature rupture of membranes and 
postpartum hemorrhage. Pregnancy in 
classical and hypermobility type EDS has 
a relative favorable maternal and neonatal 
outcome. Pregnancy in vascular type EDS 
patients is associated with severe 
complications including maternal mortality 
[12-19]. The effect of TNX deficiency on 
pregnancy has not been studied so far and 
only one case report of pregnancy in a 
TNX-deficient woman has been reported 
in the literature [10]. Here we present a 
study of all known pregnancies and genito-
urinary (GU) abnormalities in TNX-
deficient woman of reproductive age 
identified [7] in our clinic and in literature 
[7;10]. Furthermore, we extended our 
studies to a TNX knockout (KO) mouse 
model in which we studied uterine 
development during pregnancy. We 
previously established that TNX is 
essential for development of tissue 
strength in skin and is able to bind to 
elastin, a major component of elastic 
fibers, and collagens type I, III, V and XII 
[20-22]. We investigated expression of 
these molecules at the protein level. 
 
MATERIALS AND METHODS 
 
TNX-deficient patients 
We investigated pregnancies and GU 
abnormalities in all currently identified 
female tenascin-X deficient patients of 
reproductive age identified in our clinic and 
in literature. The study protocol was 
approved by the local medical ethics 
committee, and written informed consent 
was obtained from the patients. 
 
Experimental animals 
TNX knockout mice were obtained as 
described previously [23]. For all studies, 
we used TNX KO mice that were crossed 
back with six generations of C57/BL6N 
mice. Wild type C57/BL6 (WT) mice were 
used as a control. All mice used to 
investigate pregnancy abnormalities and 
morphological changes in uterus tissue 
were between 2 to 6 months of age, 
reflecting a normal age distribution of a 
breeding mice population. Skin samples 
were taken from 2 month and 9 month old 
mice, aortic tissue was obtained from 9 
month old mice. The experimental design 
was approved by the animal use 
committee of the Radboud University 
Nijmegen. 
 
Breeding 
Breeding pairs were kept in a five to one 
female:male ratio. Females were 
inspected daily for vaginal plugs and those 
with plugs were isolated and inspected 
each day for abnormalities and 
progression of pregnancy. Litter size was 
determined after birth. Neonatal survival is 
defined as the difference in litter size after 
partus and 2 weeks postpartum. 
 
Processing of samples for 
(immuno)histochemistry 
Mice were sacrificed in a sealed 
compartment by exposure to a mixture of 
carbogen gas and increasing 
concentrations of CO2. Skin samples for 
frozen sections were embedded in Tissue-
Tek O.C.T. compound (Sakura Finetek 
Europe B.V., NL) and snap frozen in liquid 
nitrogen. Skin samples for paraffin 
sections were fixed in 4% buffered 
formalin for four hours.  
 
Affinity purified TNX antibody 
production 
TNX FNIII repeats 27-32 were amplified by 
PCR (forward primer 5’-GGAATTCGAGCT 
ACCTCCCCAC-3’, reverse primer 5’-
CAGGTCGACTCAGGTGAAAGAGGTGG
A-3’) using a previously described 2.7 kb 
human TNX cDNA as a template [24]. The 
PCR product was ligated into the 
pCR2.1TOPO vector (Invitrogen, Breda, 
NL) according to the manufacturer’s 
instructions for easy digestion with 
restriction enzymes. The pCR2.1 TOPO 
vector with insert was digested with EcoRI 
and SalI. The region coding for FNIII27-32 
was inserted into the EcoRI/SalI site of the 
pET28(a)+ plasmid (Brunschwig Chemie 
B.V., Amsterdam, NL). The sequence of 
the TNX domains was verified by dideoxy 
sequencing with a 3730 DNA analyser 
(Applied Biosystems, Nieuwekerk a/d 
IJssel, NL). TNX FNIII27-32 protein was 
expressed and purified according to the 
manufacturer’s instructions (Brunschwig 
Chemie B.V., Amsterdam, NL). Purified 
TNX FNIII27-32 protein was used for 
immunization of a rabbit. Aliquots of 500 
µg TNX FNIII27-32 in 500 µL of PBS were 
mixed with an equal volume of Freund’s 
complete adjuvant for the first injection 
and Freund’s incomplete adjuvant for 
boosters. Three injections were 
administered subcutaneously at 3-week 
intervals. Polyclonal antibodies against 
TNX FNIII27-32 were purified by affinity 
chromatography on a column with antigen 
coupled to CNBr-activated sepharose 4B 
(GE Healthcare Life Sciences, Diegem, 
BE).  
Histochemistry and immunohisto-
chemistry 
Staining of elastic fibers was performed by 
modified Hart’s stain on paraffin sections 
(7 µm) [25]. Paraffin sections were also 
stained with H&E stain to assess uterus 
morphology. Frozen sections (7 µm) were 
stained with antibodies against collagen 
types I, III and V (SouthernBiotech, US) 
and elastin (Elastin Products Company 
Inc., US) as previously described by us 
[20]. Collagen XII was stained as 
previously described [22]. TNX was 
stained with affinity-purified antibodies 
directed against FNIII27-32 of TNX. 
Detection was performed with fluorescein 
isothiocyanate (FITC, green, 
Dakocytomation, DK) and Alexa Fluor 594 
(AF594, red, Molecular Probes, NL) 
labeled antibodies. Cell nuclei were made 
visible with a DAPI (blue) (Molecular 
Probes, NL) counterstaining. 
 
Table 1: Pregnancy in TNX-deficient woman. 
 
# Sex/Age (yr) G#P# GU *Specification 
1 F/50 
 
G1P1 -  
2 F/60 
Sister of #1 
 
G2P2 + VUE after uterine prolapse (at age 49) 
+ Vaginal prolapse 2 weeks after VUE 
 
3 F/46* G0P0 - *Was born premature (week 35) with 
shoulder luxation, rectal prolapse at 
age 1  
 
4 F/51 
Sister of #3 
 
G3P3 + One incident of hemorrhage post 
    partum  (>1000 ml blood loss) 
 
5 F/38 
 
G0P0* - *CAH  
6 F/51* G3P2 + IUD (24 weeks) with relatively large 
   blood loss 
+ Undefined prolapse (at age 36) 
*Deceased at age 51, severe co-
morbidity including cardiomyopathy, 
arrhythmia, arteriosclerosis and 
amputation of left leg [7] 
 
7 F/57* G4P4 + Precipitious second stage at term for 
   all births  
+ Uterine prolapse (at age 20), also 
    recurrent rectal prolapses 
*Lindor et al. [10] 
 
G#P#: Gravida # Para #, GU: Genito-Urinary, VUE: Vaginal Uterine Extirpation, IUD: Intra Uterine Death, CAH: 
Congenital Adrenal Hyperplasia. 
 
 
Figure 1: TNX KO mice abnormalities. 
(a) Although the difference in the length of 
pregnancy between TNX KO and WT mice is 
found non-significant by Fisher exact test, a 
decreasing trend in the length of pregnancy of 
TNX KO mouse compared to WT mice can be 
observed. Vaginal plugs, which are present 
after mating, are much more difficult to asses in 
TNX KO mice than in WT mice. This results in a 
significant increase of pregnancies in which the 
insemination date was unknown as shown in 
panel (b). In this study no uterine prolapses 
have been observed, however, some TNX KO 
mice suffer from a rectal prolapse as shown in 
panel (c). Rectal prolapses are also observed in 
TNX-deficient patients, although the incidence 
in TNX KO mouse appears low. (* p<0.025, chi 
square test).  
 
 
Electron microscopy 
For electron microscopy, WT and TNX KO 
samples from uterine wall at 3 weeks post-
partum, skin from 2 month-old and 9 
month-old mice, and aortas from 9 month-
old mice were fixed in 3% glutaraldehyde 
in 0.1 M sodium cacodylate overnight, and 
washed in 0.1 M sodium cacodylate buffer. 
The tissues were then sequentially treated 
with osmium tetroxide, tannic acid and 
uranyl acetate, then dehydrated and 
embedded in epon as previously 
described [26]. Thin sections (60 nm) were 
counterstained with 7% uranyl acetate in 
absolute methanol and lead citrate, and 
examined using a Tecnai 12 transmission 
electron microscope at 120kV. 
 
Statistics 
For statistical analyses, the Fisher’s exact 
or chi-square tests were used where 
appropriate for proportional data. 
Student’s t-test was used to compare 
mean litter size after partus and neonatal 
survival (difference in litter size after partus 
and 2 weeks postpartum). A p-value of 
<0.05 was considered statistically 
significant. 
 
RESULTS 
 
Pregnancy in TNX-deficient patients 
We investigated pregnancy and GU 
abnormalities in TNX-deficient woman of 
reproductive age. General reproduction 
characteristics and GU abnormalities of 
female TNX-deficient patients are 
presented in table 1. Maternal and 
neonatal outcome was generally normal; 
one out of thirteen pregnancies resulted in 
an intrauterine death of the fetus. Tissue 
laxity of TNX-deficient patients is 
demonstrated by the occurrence of 
vaginal, uterine and rectal prolapses, even 
at a relative young age. One case of 
postpartum hemorrhage was observed in 
twelve childbirths. None of our patients 
had urinary incontinence symptoms. TNX-
deficient EDS is an autosomal recessive 
disorder, therefore all offspring of a TNX-
deficient patient and an unaffected 
individual are obligatory heterozygotes. 
We have previously found that 
approximately 60% of adult females that 
are haploinsufficient for TNX suffer from 
hypermobility type EDS or benign joint 
hypermobility syndrome [8]. We found no 
obvious abnormalities (e.g. floppy infant 
syndrome, premature birth) in the 
neonates (obligatory heterozygotes) of our 
TNX-deficient population however, some 
TNX-deficient patients themselves were 
born prematurely (table 1, [10]).  
 
Pregnancy in TNX KO mice 
We investigated GU and pregnancy-
related abnormalities in TNX KO and WT 
mice ranging between 2-6 months of age. 
Litter size (TNX KO: 7 ± 2 pups, WT: 7 ± 3 
pups) and neonatal survival (TNX KO: 
74% ± 36%, WT: 54% ± 40%) did not differ 
significantly (student’s t-test). GU 
abnormalities of the TNX KO and WT mice 
are presented in table 2. Overall, we noted 
relatively few pregnancy-related 
abnormalities. Obstruction of the uterine or 
vaginal canals during partus resulting in a 
failure to deliver pups was noted more 
often in WT mice compared to TNX KO 
mice, but the difference was not significant 
(Chi-square test). A decrease in the length 
of term for the TNX KO mice can be 
observed in figure 1a, although this trend 
is not significant (Fisher’s exact test).
 
 
Table 2: Pregnancy in TNX-deficient mice. 
 
 TNX KO mice WT mice 
 number of mice number of mice 
Maternal death during pregnancy 1 0 
Miscarriage 2 0 
Obstruction during partus 1 3 
Excessive bleeding of vagina (as seen at vaginal 
plug check) 
2 0 
Cannibalism after partus 1 1 
Total number of evaluated pregnancies 36 31 
 
 
A striking difference between TNX KO and 
WT was found for the location of the 
vaginal plug that is present after mating. 
Generally, the vaginal plug in TNX KO 
mice was located much deeper in the 
vaginal canal than in WT mice. This made 
identification of vaginal plugs in TNX KO 
mice markedly more difficult, resulting in a 
significant increase in pregnancies with 
unknown length of pregnancy (figure 1b, 
Chi-square test). No uterine or rectal 
prolapses were observed in this particular 
study (67 pregnancies of KO and WT 
mice). We did, however, occasionally 
observe rectal prolapse in the breeding 
colony of our TNX KO mice population 
(shown in figure 1c).  
 
Structure of the mouse uterus 
In figure 2, H&E stained sections of the 
uterus of WT (figure 2a) and TNX KO mice 
(figure 2b) are shown. The mouse uterus 
consists of three layers: an outer layer, 
that includes the single-cell layered 
perimetrium and a thin layer of connective 
tissue; a muscular layer, the myometrium, 
composed of two oppositely orientated 
layers of muscle; and an endometrium, 
consisting of loose connective tissue 
covered by epithelium, which undergoes 
remodeling during the menstrual cycle and 
pregnancy. No differences in structure of 
the uterus were noticeable between TNX 
KO and WT mice (figure 2, as shown for 
uteri 1 day postpartum). 
 
Immunostaining of TNX in the mouse 
uterus 
TNX is present throughout the uterus of 
virgin mice and in the uterus during and 
after pregnancy (figure 3a-c). 
Immunostaining of TNX appears weak and 
discontinuous in the perimetrium (figure 
3a-c and f). TNX is present in the 
endometrium, although the epithelium, 
which lines the endometrium, is negative 
for TNX (figure 3d). TNX is abundantly 
present in the layers of connective tissue 
ensheathing muscle bundles of the 
myometrium (figure 3f). Overall, no change 
in the localization of TNX immunostaining 
was observed during and after pregnancy. 
Specificity of our TNX antibody is 
demonstrated by the complete absence of 
positive staining in the TNX KO mouse 
tissues (figure 3e and g). 
 
Immunostaining of collagen in the 
mouse uterus 
We previously demonstrated binding and 
colocalization of TNX in skin with collagen 
type I, II and V [20;21]. In the uterus, TNX 
also colocalizes with major fibrillar 
collagens type I, III and V as is shown for 
uteri 3 weeks postpartum (figure 4). The 
collagens are present in the perimetrium, 
endometrium and the layers of connective 
tissue ensheathing muscle bundles of the 
myometrium. Similar results were obtained 
for uteri from virgin, 13 days pregnant and 
1-day postpartum mice. No difference in 
collagen type I, III and V immunostaining 
was found between WT and TNX KO mice 
(data not shown), which is in line with our 
observations in skin [20]. Collagen type 
XII, an interaction partner of TNX [22], is 
present throughout the uterus (figure 5). 
The immunostaining appears the strongest 
in the transverse muscle bundles of the 
myometrium around blood vessels (BV) 
and around the lumen although the signal 
intensity is not always completely 
continuous around the lumen and blood 
vessels. TNX and collagen type XII are 
both present throughout the entire uterus, 
however, the strongest collagen type XII 
immunostaining is observed in the 
transverse muscle bundles of the
 
 
Figure 2: Structure of the TNX KO and WT uterus.
H&E stained sections of the uterus of WT mice (a) and 
of TNX KO mice (b) are shown. No differences in 
structure of the uterus were noticeable between TNX 
KO and WT mice. The uterus of mice consists of a thin 
outer layer, the perimetrium (denoted as P). A muscle 
layer, the myometrium (denoted as M), consist of two 
oppositely orientated layers of muscle, although this is 
difficult to distinguish in H&E stained slides. The 
endometrium (denoted as E) consist of loose 
connective tissue. The endometrium is separated from 
the lumen (denoted as L) by an epithelium. Bars are 
0.01 mm. 
 
 
 
Figure 3: Immunostaining of TNX in the uterus. 
TNX (green) is present throughout the uterus of virgin mice (a) and in the uterus during and after pregnancy 
(shown for 13 days pregnant (b) and 3 weeks postpartum (c) uteri). Cell nuclei are stained with DAPI (blue). TNX 
is present in the endometrium (d) and the layers of connective tissue ensheathing muscle bundles of the 
myometrium (f). The TNX staining of the perimetrium can be relatively weak (a-c and f). The epithelium of the 
lumen is negative for TNX (d). Specificity of our TNX antibody is demonstrated in figures (e) and (g). Panels (d-g) 
are from uteri 3 weeks postpartum. Bars are 50 µm (P = perimetrium, M = myometrium; longtidunal muscle 
bundles, M* = myometrium; transverse muscle bundles, E = endometrium, Epi = epithelium of the lumen, L = 
lumen). 
 
myometrium, whereas the TNX 
immunostaining in the ECM of these 
bundles is relatively weak compared to the 
rest of the uterus (figure 3a-c,f). No 
differences in the collagen type XII 
localization in the uterus between WT 
(figure 5a) and TNX KO (figure 5b) mice 
were observed.  
Elastic fibers in mouse tissues 
Elastic fibers in the skin of TNX-deficient 
patients are known to be abnormally 
shaped [27] and thus we investigated their 
structure in TNX KO mouse tissues. 
Elastic fibers in the uterus are mostly 
located in the myometrium and 
perimetrium (figure 6a and b).  
 
Figure 4: TNX colocalizes with major fibrillar collagens type I, III and V. 
TNX (green) and collagen types I (a), III (b) and V (c) (red) colocalize (yellow to orange) as is shown for uteri 3 
weeks postpartum. Similar results were obtained for uteri from virgin, 13 days pregnant and 1-day postpartum 
mice. No difference in collagen type I, III and V immunostaining was found between WT and TNX KO mice (data 
not shown). Bars are 50 µm (P = perimetrium, M = myometrium; longtidunal muscle bundles, M* = myometrium; 
transverse muscle bundles, E = endometrium, Epi = epithelium of the lumen, L = lumen). 
 
 
 
Figure 5: Immunostaining of collagen type XII in 
uterus. 
Collagen XII (red) is present throughout the uterus. The 
immunostaining appears the strongest in the transverse 
muscle bundles of the myometrium (M*), around blood 
vessels (BV) and around the lumen (L), although the 
signal intensity is not always completely continuous. No 
differences in the collagen type XII localization in the 
uterus between WT (a) and TNX KO (b) mice were 
observed. Bars are 50 µm (P = perimetrium, M = 
myometrium; longtidunal muscle bundles, M* = 
myometrium; transverse muscle bundles, BV = blood 
vessel, E = endometrium, L = lumen). 
 
 
 
Figure 6: Elastin and elastic fibers in the uterus. 
Elastic fibers (purple, modified Hart’s staining) are mostly located in the myometrium (M, M*) and perimetrium (P), 
whereas the endometrium (E) appears to contain fewer elastic fibers as shown for WT (a) and TNX KO mice (b). 
No elastic fiber abnormalities were found in the TNX KO mice. Elastin (red) immunostaining is observed in the 
myometrium, predominantly in the transverse bundles (M*) as shown in panels (c) and (d). The layers of 
connective tissue ensheathing muscle bundles of the myometrium (M) and perimetrium (P) are stained positive 
for elastin (red). Strong elastin staining is also seen in the endometrium (E). Elastin immunoreactivity was similar 
for WT (c) and TNX KO mice (d). Elastin (red) colocalizes (orange) with TNX (green) as shown in the myometrium 
(M*) (e). Not all TNX colocalizes with elastin as TNX also colocalizes with different collagen types (fig. 4). Bars 
are 50 µm (P = perimetrium, M = myometrium; longtidunal muscle bundles, M* = myometrium; transverse muscle 
bundles, BV = blood vessel, E = endometrium, L = lumen). 
 
The endometrium contains few elastic 
fibers as shown for WT (figure 6a) and 
TNX KO mice (figure 6b). In the 
myometrium and perimetrium, positive 
staining for elastin is seen predominantly 
in the layers of connective tissue 
ensheathing the transverse muscle 
bundles (figure 6c and d). Despite the 
relative low abundance of mature elastic 
fibers seen in the endometrium, the 
presence of elastin could be detected by 
immunohistochemistry, possibly a 
consequence of sensitivity of the detection 
methods (figure 6c-d). Elastin localization 
was similar for WT (figure 6c) and TNX KO 
mice (figure 6d). We previously 
demonstrated binding of TNX with elastin 
and the colocalization of these two 
proteins in skin [20;21].  Consistent with 
these findings, elastin also colocalizes with 
TNX in the uterus as shown in the 
myometrium (figure 6e). In previous work, 
we showed an increase in elastin positive 
material in the skin of aging TNX KO mice 
[20;21]. Although by light microscopy, the 
elastic fibers in the TNX KO mouse skin 
did not appear to be abnormally shaped, 
an increase in staining could have resulted 
from an increase in less mature or less 
organized elastin fibers, an increase in 
soluble tropoelastin within the matrix 
and/or the consequence of more 
immunoreactive epitopes being available 
due to an increased susceptibility for 
degradation. These results are consistent 
with our past observations of elastic fibers 
in the skin of TNX-deficient patients, 
where irregular and immature elastic fibers 
and fibers devoid of microfibrils could be 
seen at the ultrastructural level [20;27].
  
Figure 7: Ultrastructural 
evaluation of elastic fibers. 
Elastic fibers in WT (a) and TNX 
KO mice (b) uterus do not 
appear to differ in shape or size. 
The dark structures indicated by 
arrows are elastic fibers (shown 
for uterus 3 weeks postpartum). 
The elastic laminae (one 
indicated by an arrow in each 
slide) in the aorta of WT (c) and 
TNX KO mice (d) are similar in 
shape and number (aorta of 9 
month-old mice). Skin of older 
TNX KO mice (9 months old) 
show differences in elastic fibers 
compared to WT skin. Irregular 
elastin aggregates can be 
observed in the TNX KO mouse 
skin (e, near a sebaceous 
gland). An enlargement of an 
elastin aggregate, indicated by 
an arrow, is shown in (f). These 
aggregates were not found in 
skin of 2 month old TNX KO 
mice nor in 9 month old WT 
mice. No irregularities in the 
shape of elastic fibers are 
observed in 9 month old TNX 
KO mice skin, however, larger 
elastic fibers than in WT mice 
(g) are often observed in the 
TNX KO mice (h, arrows 
indicate elastic fibers). Bars in 
panel (a) and  (b) are 0.5 µm, in 
panel (c) and (d) 10 µm, in 
panel (e), (g) and (h) 2 µm and 
in panel (f) 1 µm. 
 
Thus, to further expand these findings in 
skin and to investigate the elastic fibers in 
the uterus, we performed an ultrastructural 
analysis of the elastic fibers in several 
tissues. Elastic fibers in WT (figure 7a) and 
TNX KO mice (figure 7b) uteri do not 
appear to differ in shape or size (shown for 
uterus 3 weeks postpartum). Similarly, in 
aorta the elastic laminae (one indicated by 
an arrow in each slide) of WT (figure 7c) 
and TNX KO mice (figure 7d) are similar in 
shape and number (aorta of 9 month old 
mice). In skin of older TNX KO mice (9 
months old), however, a difference in 
elastic fiber ultrastructure was observed 
compared to WT skin. In addition to 
normal appearing elastic fibers, irregular 
elastin aggregates, as seen in the skin of 
TNX-deficient patients [27], could be 
observed (figure 7e and f). These elastin 
aggregates were not found in skin of 2 
month old TNX KO mice or in 9 month old 
WT mice. Interestingly, elastic fibers in 
skin of 9 month old TNX KO mice often 
appear larger compared to WT mice of the 
same age (compare figures 7g and h).  
 
DISCUSSION 
GU complications occur frequently in 
patients with various types of EDS 
[12;13;16-19]. In classical and 
hypermobility types of EDS, which are the 
most common, the outcome of pregnancy 
is generally favorable. Maternal 
complications however, such as 
postpartum hemorrhage and pelvic 
instability, are more common than in the 
general population [16;18;19]. 
Furthermore, EDS patients appear to have 
an elevated risk of uterine prolapse 
[13;17]. Pregnancy in patients with 
vascular type EDS may even lead to 
maternal death through uterus or vessel 
rupture [12]. We investigated pregnancies 
and GU abnormalities in all known TNX-
deficient woman of reproductive age. 
Generally, pregnancy was without major 
complications in TNX-deficient patients 
apart from one incident of postpartum 
hemorrhage. However, uterine and vaginal 
prolapse regularly occur in TNX-deficient 
women, even at a young age, suggesting 
laxity of GU tissues. Premature rupture of 
fetal membranes is a risk in pregnancy 
with EDS affected fetuses [17;19]. No 
premature births were observed in the 
offspring of the TNX-deficient patients, 
however, some TNX-deficient patients had 
been born premature. 
Complete TNX deficiency in 
humans is a rare condition, and so far only 
few patients have been identified. We 
therefore investigated pregnancy and 
uterine tissue structure in our TNX KO 
mouse model. No gross, significant 
differences were found in abnormalities 
during pregnancy or reproduction between 
the TNX KO and WT mice. There was a 
trend towards a reduction in the length of 
pregnancy in TNX KO mice. The only 
significant difference was observed in the 
location of the vaginal plugs, which 
suggests laxity in the vaginal wall.  
 In a previous study, we did not find 
any differences in cutaneous collagen 
deposition between TNX KO and WT mice 
[20], as has been observed in the skin of 
TNX-deficient patients [7;27]. Alterations in 
collagen deposition in the skin of TNX KO 
mice is, however, a matter of debate 
[20;23;28]. In the present study, we found 
elastin aggregates and enlarged elastic 
fibers in 9 month old skin of TNX KO mice 
at the ultrastructural level, which is in 
accordance with our previous published 
data on increased elastin staining in aging 
TNX KO mouse skin [20]. We found no 
differences in elastic fibers in the uterus or 
elastic laminae of the abdominal aorta 
between TNX KO and WT mice 
suggesting a specific role for TNX in the 
maturation or maintenance of elastic fibers 
in skin. However, abnormal elastic fibers 
might not be present in the uterus since 
the ECM is constantly being remodeled in 
the menstrual cycle and in pregnancy.  
Although the TNX KO mice appear 
to have a much milder phenotype 
compared to TNX-deficient humans, the 
skin of TNX KO mice is significantly 
weaker and more lax compared to WT 
mice [6;7;10;20;23;27-30]. Our data 
suggest a more lax vaginal canal in TNX-
deficient patients and to a certain degree 
in TNX KO mice. It is attractive to 
speculate, considering the observations 
from all our studies in mice, that TNX is 
essential for tissue integrity, independent 
of the quantity of collagen deposition or 
elastic fiber structure. In conclusion, we 
would advise obstetricians and 
gynecologists to monitor TNX-deficient 
patients more closely as they are likely to 
have weaker GU connective tissue, could 
therefore be at risk for GU complications. 
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Abstract Tenascin-X (TNX) is a large 450 kDa extra-
cellular matrix protein expressed in a variety of tissues
including skin, joints and blood vessels. DeWciency of
TNX causes a recessive form of Ehlers–Danlos syn-
drome characterized by joint hypermobility, skin fra-
gility and hyperextensible skin. Skin of TNX deWcient
patients shows abnormal elastic Wbers and reduced col-
lagen deposition. The mechanism by which TNX deW-
ciency leads to connective tissue alterations is unknown.
Here we report that C-terminal domains of human
TNX bind to major dermal Wbrillar collagens and trop-
oelastin. We have mapped these interactions to the
Wbronectin type III repeat 29 (FNIII29) and the C-ter-
minal Wbrinogen domain (FbgX) of TNX. In addition
we found that FNIII29 of TNX accelerates collagen
Wbrillogenesis in vitro. We hypothesize that TNX con-
tributes to matrix stability and is possibly involved in
collagen Wbril formation.
Keywords Tenascin-X · Collagen · Elastin · 
Fibrillogenesis · Ehlers–Danlos syndrome
Introduction
Tenascin-X is a large extracellular matrix glycoprotein
composed of EGF like-repeats, Wbronectin type III
(FNIII) repeats and a C-terminal Wbrinogen domain
(FbgX) [1, 5, 6, 12]. TNX abnormalities are associated
with several pathological conditions [2, 22, 27]. Com-
plete deWciency of TNX in humans leads to a recessive
form of Ehlers Danlos syndrome (EDS) and TNX hap-
loinsuYciency is a cause of hypermobility type EDS.
The skin of TNX deWcient patients is markedly lax with
poor recoil properties and shows easy bruising [2, 14,
20, 22, 27]. We have previously shown TNX to be pres-
ent in the entire dermis of healthy individuals. During
development in mice TNX colocalises with the major
Wbrillar collagens and elastic Wbers in the dermis [3, 22].
Adult TNX deWcient patients show abnormal elastic
Wbers and reduced collagen deposition in skin [28]. The
mechanism by which TNX deWciency leads to altera-
tions in the extracellular matrix (ECM) is unknown.
Mapping of TNX domains that interact with compo-
nents of the elastic Wbers or collagen is therefore an
important step to deWne the role of TNX in connective
tissue biology of human skin.
It has previously been shown that bovine and
murine TNX bind to heparin [13, 16]. In bovine TNX a
conformational heparin-binding site has been identi-
Wed involving FNIII repeats 10 and 11 in the N-terminal
half of the molecule. This heparin-binding site is also
involved in the binding of TNX to decorin, and it was
proposed that TNX interacts with collagen through
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decorin [4]. Minamitani et al. showed that the short
isoform of murine TNX binds directly to collagen type
I, probably through interaction with one of the Wbro-
nectin type III repeats. This short isoform was found to
promote collagen Wbrillogenesis in vitro [18].
The aim of our study was to investigate the molecular
mechanisms of the observed phenotype in TNX-deW-
cient EDS patients. We therefore analyzed interactions
of human TNX with elastic Wber components and with
the major Wbrillar collagens in the dermis (collagen
type I, III and V). We found that the C-terminus of
TNX harbors potential interaction sites with collagens
type I, III and V and tropoelastin (TE), which are con-
stituents of the anatomical structures that are abnor-
mal in the dermis of these patients.
Materials and methods
Expression and puriWcation of recombinant 
TNX fragments
The TNX fragments were ampliWed by PCR with the
primers listed in Table 1 using a previously described
2.7 kb human TNX cDNA [19] as a template. PCR
products were ligated into the pCR2.1TOPO vector
(Invitrogen, Breda, NL) according to the manufac-
turer’s instructions for easy digestion with restriction
enzymes. The pCR2.1 TOPO vectors with inserts were
digested with EcoRI and SalI and cloned into the
EcoRI/SalI site of the pMal-c2X plasmid (Westburg
B.V., Leusden, NL). Subsequently the DNA sequences
coding for FNIII29 and FNIII29–30 of TNX were
cloned into the EcoRI/SalI site of the pGex-4T1 plas-
mid (GE Healthcare Life Sciences, Diegem, BE). The
sequence of the TNX domains was veriWed by dideoxy
sequencing with a 3730 DNA analyzer (Applied Bio-
systems, Nieuwekerk a/d IJssel, NL). TNX fragments
were obtained as maltose binding protein (MBP)
fusion proteins using E.coli TOP10F’ cells (Invitrogen)
according to the manufacturer’s instructions. MBP
fusion proteins were isolated on amylose resin columns
and analyzed for purity with SDS-PAGE. MBP fusion
proteins were incubated with factor Xa (Westburg
B.V.) in an attempt to remove the MBP tag from the
fusion protein according to the manufacturer’s instruc-
tions. FNIII29–30 without tag was obtained by proteolytic
cleavage of FNIII29–30 from a glutathione-S-transfer-
ase (GST) fusion protein bound to a glutathione-
sepharose4B column (GE Healthcare Life Sciences)
according to the manufacturer’s instructions.
Proteins and antibodies
A 100 kDa C-terminal recombinant TNX protein, con-
taining six FNIII repeats and a Wbrinogen domain,
encoded by a 2.7 kb TNX sequence has previously
been described by Tee et al. [19, 23]. MBP–FNIII27–
28, MBP–FNIII28–29, MBP–FNIII29, MBP–FNIII29–
30, MBP–FNIII30–31, MBP–FbgX and FNIII29–30
were obtained as described in the previous section.
Human Collagen type I from Chemicon Interna-
tional (Chemicon International, Temecula, CA, USA),
human collagen type III and V from Rockland Inc
(Tebu-bio, Heerhugowaard, NL). Bovine collagen type
I (acid soluble) was obtained from BD biosciences (BD
Biosciences, Alphen aan den Rijn, NL). Recombinant
bovine tropoelastin (bTE) was a generous gift from Dr.
R. Mecham (Washington University, St. Louis, MO,
USA) [10]. Human recombinant Wbrillin domains, Tb2-
cbEGF11, Tb3-cbFGF11, cbEGF11–14, cbEGF22–23,
cbEGF28–30, tb6-cbEGF32, cbEGF32–36, tb7-cbEGF37,
were generously donated by Dr. P.A. Handford
(Oxford University, Oxford, UK) [7, 9, 11, 17, 24, 25].
BSA and gelatin were obtained from Sigma–Aldrich
(Sigma–Aldrich Chemie B.V., Zwijndrecht, NL). BSA
was used as a negative control. MBP was obtained
from New England Biolabs (Westburg B.V.) and used
as a negative control.
We used monoclonal antibodies speciWc for MBP
(Westburg B.V) and a previously described guinea pig-
anti-TNX serum [22] for detection of untagged
100 kDa TNX and MBP-TNX-domains in our solid-
phase assays. Pre-immunization serum was used as a
Table 1 TNX domains and primers
The EcoRI and SalI restriction sites are underlined in the primer sequences. Each SalI site is preceded by a stop codon (TCA), except
for the Wbrinogen domain, which already contains a stop codon at the 3 end of the sequence
TNX domains Forward primer Reverse primer
FNIII27–28 5-GGAATTCGAGCTACCTCCCCAC-3 5-CTCGTCGACTCACTGACCAGCAGGAGC-3
FNIII28–29 5-CTGAATTCCCTGAAGAGCCCCGC-3 5-TGGGTCGACTCAGCGGGCGGTTCCCTG-3
FNIII29 5-TCAGAATTCTCAAGGCCCCGCCTG-3 5-TGGGTCGACTCAGCGGGCGGTTCCCTG-3
FNIII29–30 5-TCAGAATTCTCAAGGCCCCGCCTG-3 5-GAAGTCGACTCAAGGCTCACTCTCCTC-3
FNIII30–31 5-ACCGAATTCACCCTCAGCCCAGTT-3 5-GTGTCGACTCAGATGCTGGCTGGGG-3
FbgX 5-TCTGAATTCACGGGTGGGCTGCGG-3 5-GGGTCGACAGAGAGGTGGGCAGCA-3
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negative control [22] FNIII29–30 of TNX was detected
with a new aYnity puriWed polyclonal rabbit antiserum,
raised against a MBP–FNIII29–30 antigen.
Collagen Wbrillogenesis assays
Native bovine type I collagen (BD Biosciences,
Alphen aan den Rijn, NL) 2.9 mg/ml in 0.012 N HCl, as
provided by the manufacturer, was dissolved in PBS.
MBP, BSA, MBP–FNIII29, FNIII29–30 and 100 kDa
TNX were added to samples in cuvettes after which the
Wnal volume was adjusted to 1 ml of 0.4 mg/ml collagen
type I with PBS and incubated at 30°C. Turbidity
change was measured by monitoring the change in
absorbance at 400 nm in a UV-160A Shimadzu spec-
trophotometer (Shimadzu Benelux, Den Bosch, NL) at
Wxed intervals. Data points represent the mean of trip-
licate measurements.
Binding assays
Ninety-six well microtiter plates (Greiner Bio-One
B.V., Alphen aan den Rijn, NL) were coated overnight
at 4°C with ECM components diluted in PBS. All fur-
ther incubation steps were performed at 37°C. After
each incubation step wells were washed with PBS con-
taining 0.05% Tween-20 (T-PBS). Wells were satu-
rated with 1% BSA in T-PBS for 2 h and then
incubated with recombinant TNX domains for 1 h.
This was followed by incubation with antibodies
against the recombinant TNX fragments for 1 h.
Thereafter, wells were incubated with biotinylated anti
guinea pig (Vector Laboratories Inc., Burlingame, CA,
USA), biotinylated anti rabbit (Vector Laboratories
Inc.) or anti mouse IgG (vectastain kit, Brunschwig
Chemie, Amsterdam, NL) for 1 h followed by a 45 min
incubation with an avidin–biotin–horse radish peroxi-
dase mixture (vectastain kit, Brunschwig Chemie).
Bound peroxidase was detected with o-phenylenedi-
amine dihydrochlorid (Perbio Science Nederland
B.V., Etten-Leur, NL) and the absorbance read at
490 nm. All antibodies and TNX proteins were
diluted in T-PBS containing 0.1% BSA. PBS was
substituted by tris buVered saline (TBS) + 5 mM
Ca2Cl2 in solid phase assays in which binding of TNX
to Wbrillin-1 domains was investigated for proper fold-
ing/stability of the Wbrillin-1 domains [7, 21]. Assays
were performed at least twice. BSA, MBP and pre
immunization guinea pig serum were used as negative
controls or baseline correction.
As an alternative to the binding assay in ELISA for-
mat we investigated binding of MBP–FNIII29 to colla-
gen Wbrils generated during the Wbrillogenesis assay.
BrieXy, various concentrations of MBP–FNIII29 were
incubated overnight at 30°C in the presence of 0.1%
BSA or collagen type I (0.4 mg/ml) + 0.1% BSA.
Thereafter, the insoluble collagen Wbrils were pelleted
by centrifugation. The concentration of MBP–FNIII29
in the supernatant was determined using an assay simi-
lar to a previous described one [22] in which, instead of
guinea pig anti TNX antiserum, fusion protein was
detected with monoclonal antibodies speciWc for MBP
(Westburg B.V.).
SDS-PAGE analysis
Proteins were loaded onto 12% Bis–Tris gels (Invitro-
gen) gel electrophoresis was carried out using the
NuPAGE system according to the manufacturer’s
instructions (Invitrogen). To analyze protein purity
gels were stained using coomassie brilliant blue R250
(Brunschwig).
Results
Binding of C-terminal 100 kDa TNX to extracellular 
matrix components
We postulated that TNX might interact with compo-
nents of elastic Wbers or collagens directly because of
the disturbed properties of collagens and elastic Wbers
in TNX deWcient patients. As a Wrst approach to iden-
tify extracellular ligands of TNX, we performed solid
phase assays to test binding of a recombinant C-termi-
nal 100 kDa TNX fragment [19, 23] (soluble phase) to
ECM molecules (immobilized substrates). Figure 1 a
shows that TNX binds dose dependently to human col-
lagens type I, III and V. Binding to BSA, which served
as a negative control, was absent. Figure 1b compares
the relative values of recombinant C-terminal 100 kDa
TNX binding to human Wbrillar collagens, at the high-
est concentration of fusion protein compared to the
control values of BSA. Figure 2 a shows the interaction
of TNX with bovine collagen type I, bovine tropoela-
stin and denatured collagen type I (gelatin). TNX did
not bind to denatured bovine collagen (gelatin).
Figure 2b compares the relative values of recombinant
C-terminal 100 kDa TNX binding to bovine tropoela-
stin, collagen type I and gelatin, at the highest concen-
tration of fusion protein compared to the control
values of BSA. Half maximal saturation, a measure for
the aYnity of the interaction, was reached at a concen-
tration of soluble 100 kDa TNX of 1.8 £ 10¡8 M for
human collagen type I and 4.0 £ 10¡8 M for bovine col-
lagen type I. Half maximal saturation was reached at
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1.1 £ 10¡8 M for human collagen type III, 0.8 £ 10¡8 M
for human collagen type V and 1.8 £ 10¡8 M for tropo-
elastin. We did not observe binding to several domains
of the elastic Wber protein Wbrillin-1 (data not shown).
Binding of speciWc C-terminal TNX fragments 
to extracellular matrix components
To identify the sequences in TNX responsible for bind-
ing to the ECM components we subcloned and
expressed a number of fragments from the C-terminal
100 kDa TNX protein. Figure 3 gives a schematic over-
view of these fragments, and shows the purity of the
fusion proteins used in this study. The domains studied
here were produced as MBP-fusion proteins and
included overlapping tandems of FNIII repeats and the
FbgX domain.
All recombinant proteins containing the FNIII29
repeat showed dose dependent binding to collagen
type I, III and V. As an example the binding curves for
collagen type V are shown in Fig. 4a. Only FNIII29,
FNIII28–29 and FNIII29–30 showed strong binding,
whereas no binding was observed for repeats FNIII27–
28, FNIII30–31 and the FbgX domain which yielded a
Xat line as for the MBP and BSA control. For reasons
of clarity the curves for FNIII27–28, FNIII30–31, FbgX
and BSA are not included in Fig. 4a because they coin-
cide with MBP. Figure 4b compares the relative values
of FNIII29 and FNIII27–28 binding to Wbrillar colla-
gens, at the highest concentration of fusion protein
compared to the control values of MBP.
Figure 5a depicts binding of TNX fragments to
recombinant bTE. All fusion proteins containing
FNIII29 were found to bind to TE, but in addition we
found interaction with the FbgX domain, which was
not the case for collagens. Recombinant MBP shows
some non-speciWc binding to bTE but this is clearly less
than FNIII29 and FbgX containing recombinant pro-
teins. This non-speciWc binding was also observed for
BSA, FNIII27–28 and FNIII30–31. The lines from
these proteins coincide with the line of the MBP con-
trol, therefore they were omitted from Fig. 5a for rea-
sons of clarity. Figure 5b compares the relative values
of FNIII29, FNIII27–28 and FbgX binding to recombi-
nant TE, at the highest concentration of fusion protein
compared to the control values of MBP.
We used TNX domains fused to MBP because this
allows simple high yield puriWcation and—impor-
tantly—it allows comparison and easy detection of
bound fusion proteins by a single anti-MBP antibody.
Fig. 1 Binding of recombinant C-terminal 100 kDa TNX to hu-
man collagen type I, III and V. a TNX binds dose dependently to
human collagens type I, III and V. Binding to BSA, which served
as a negative control, was absent. b Comparisons of binding of re-
combinant C-terminal 100 kDa TNX and BSA to collagens type
I, III, and V at the highest concentration used (10 M)
Fig. 2 Binding of recombinant C-terminal 100 kDa TNX to bo-
vine collagen type I and bTE. a TNX binds dose dependently to
bTE and bovine collagen type I. No binding to denatured bovine
collagen type I (gelatin) was observed (the gelatin signal coin-
cides with the BSA baseline signal). b Comparison of binding of
recombinant C-terminal 100 kDa TNX and BSA to collagens
type I, III and V at the highest concentration used (10 M)
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MBP alone was used as a control throughout the stud-
ies described above. In order to check if MBP fused to
TNX domains would cause artiWcial binding of fusion
proteins to ECM molecules we decided to test binding
of a recombinant TNX fragment without MBP. Unfor-
tunately, it was not possible to produce FNIII29 as a
single repeat protein without fusion protein tag in
either the pMal protein fusion or GST gene fusion sys-
tem. We therefore produced a recombinant FNIII29–
30 repeat devoid of fusion tag and raised an antibody
against FNIII29–30. Figure 6 shows that pure recombi-
nant FNIII29–30 essentially has the same binding prop-
erties towards Wbrillar collagens and TE as the MBP-
fusion protein, indicating that the interaction site
resides in the TNX moiety (FNIII29) of the fusion pro-
teins.
Stimulation of Wbrillogenesis by FNIII29
To extend the observed binding properties of TNX
FNIII repeats at the functional level, we investigated
whether the collagen binding FNIII29 repeat of human
TNX could modulate collagen Wbrillogenesis. Using a
turbidity assay (see Fig. 7a) we found an increase in the
rate of Wbril formation and a shortening of the lag
phase in the presence of the FNIII29 repeat of TNX
compared to the control proteins (BSA (not shown)
and MBP) The Wbrillogenesis rate in the lateral growth
phase, characterized by Wbril- and aggregate formation
[8, 26], was signiWcantly increased (P < 0.001) when
48 g/ml MBP–FNIII29 was added. At a concentration
of 24 g/ml, MBP–FNIII29 does not signiWcantly inXu-
ence the lateral growth phase, although it shortens the
lag phase, characterized by linear growth of microW-
brils and early Wbril formation [8, 26], compared to
controls. After 24 h all samples reached a similar maxi-
mal OD (data not shown). FNIII29–30 had only a min-
imal eVect on collagen Wbrillogenesis compared to
MBP–FNIII29 and C-terminal 100 kDa TNX showed
no signiWcant eVect on either the lag- or lateral growth
phase of collagen Wbrillogenesis (data not shown).
The Wbrillogenesis assay also provided us with an
alternative method to investigate binding of TNX frag-
ments to ECM molecules. To investigate the binding of
MBP–FNIII29 to the collagen Wbrils formed during the
assay, we measured the amount of MBP–FNIII29 that
Fig. 3 Recombinant TNX 
proteins used in this study. 
a Coomassie staining of
recombinant proteins, lanes 
1–5 MBP–FNIII repeats, lane 
6 MBP–FbgX domain, lane 7 
FNIII29–30 repeat without 
MBP fusion tag. b Schematic 
overview of recombinant pro-
teins
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remained in the supernatant after pelleting of the insol-
uble collagen Wbrils. As shown in Fig. 7b MBP–
FNIII29 was depleted from the soluble phase, indicat-
ing pull-down by the formation of collagen Wbrils.
Discussion
We established a number of novel in vitro binding
properties of human TNX that reside in the 100 kDa
C-terminal portion. The binding properties of this frag-
ment could be largely ascribed to the FbgX domain
(tropoelastin binding) and the FNIII29 repeat, which
was found to bind strongly to tropoelastin and collagen
types I, III and V. Previous studies by others, using
bovine and murine TNX have found binding to decorin
[4] and collagen type I [18]. In the latter study, deletion
of the EGF-like repeats or the FbgX domain did not
abolish collagen binding, suggesting that binding of
murine TNX resides somewhere in the FNIII repeats.
The binding to elastin was particularly interesting, as
abnormal elastic Wber morphology is a characteristic
feature of EDS patients with a complete TNX deW-
ciency. We found binding of tropoelastin both to
FNIII29 and FbgX. In contrast to FNIII29 the FbgX
domain only binds to TE and not to other tested ECM
proteins. The functional signiWcance of this Wnding
requires further investigation, but this interaction
could be involved both in maturation or stability of the
elastic Wber.
Dermal collagen deposition is reduced in TNX deW-
cient patients, and their skin and other connective tis-
sues is fragile as witnessed by easy bruising [22, 28].
The skin strength in TNX deWcient mice is markedly
reduced, although the signiWcance and magnitude of
the reduction of collagen deposition is debated [3, 15,
18]. In mice, the variation in collagen Wbril diameter
appears to be increased [15, 18]. Speculatively, the
assembly or stability of collagen Wbrils could be dis-
turbed in TNX deWcient patients. We found that the
FNIII29 domain of human TNX is able to accelerate
Fig. 4 Binding of TNX FNIII repeats to collagen type I, III an V.
a Binding curves of recombinant TNX proteins containing
FNIII29 show dose dependent binding to Wbrillar collagens as
shown here for human collagen type V. b Comparison of binding
of MBP–FNIII29, MBP-FNIII27–28 and MBP to collagens type I,
III and V at the highest concentration used (16 M)
Fig. 5 Binding of TNX FNIII repeats and FbgX domain to TE. a
Recombinant TNX fragments containing FNIII29 and the FbgX
domain bind dose dependently to recombinant TE. The other
investigated FNIII repeats of TNX do not show signiWcant bind-
ing to bTE (not shown here). MBP alone shows non-speciWc bind-
ing which is signiWcantly lower than the TNX containing fusion
proteins. b Comparison of binding of MBP-FNIII29, MBP–
FNIII27–28, MBP–FbgX and MBP to recombinant TE at the
highest concentration used (16 M)
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the collagen Wbril formation in vitro. In contrast, how-
ever, we failed to detect a signiWcant eVect of the
100 kDa TNX fragment on Wbrillogenesis. This might
possibly be due to conformational changes caused by
folding of the 100 kDa TNX in solution that precludes
an eVect on Wbrillogenesis, although the 100 kDa frag-
ment binds to collagen type I. Alternatively, the
observed eVect of the TNX FNIII29 repeat on Wbrillo-
genesis could be artiWcial, because it is not known
whether it is accessible to collagen in the native
450 kDa protein. Minamitani et al. found that a short
isoform of murine TNX could accelerate collagen
Wbrillogenesis in an assay similar to the one we used
[18]. Interestingly, they found that deletion of the EGF
repeats or Wbrinogen domain did not have an eVect on
binding of TNX to collagen although collagen Wbrillo-
genesis kinetics were aVected by deletion of these
domains. Possibly conformational changes could
account for this aVect. Furthermore, we observed bind-
ing of the TNX FNIII29 repeat to the insoluble colla-
gen Wbrils formed during in vitro Wbrillogenesis. This is
in agreement with the observed binding properties of
this domain in our solid phase assay in ELISA format.
For Wbrillar collagens type III and V we observed that
preincubation of TNX FNIII29 with these collagens
reduced the measured amount of TNX compared to
controls in a previously described TNX ELISA [22]
(data not shown). These Wndings are in accordance
with the results from our solid phase binding assays.
Clearly, the functional consequences of the interaction
of TNX domains require further investigation. Ideally,
the complete human 450 kDa [1] or adrenal speciWc
74 kDa [23] TNX form with correct glycosylation
should be produced or puriWed, to provide deWnitive
answers with respect to molecular interactions and
eVects on Wbrillogenesis. On the other hand, the molec-
ular diversity of TNX is far bigger than anticipated. We
have found that various fragments of TNX, ranging
from 70 to 450 kDa are present in human serum
(unpublished results). Whether these represent alter-
native splice forms or posttranslationally processed
fragments is unknown. All of these TNX forms contain
the FNIII29 repeat and it is possible that these shorter
forms adopt a conformation in which FNIII29 is
exposed to exert binding to ECM molecules and causes
functional eVects.
In conclusion, our study shows that domains of TNX
directly interact with a number of ECM molecules that
form a major part of the aVected structures in the der-
mis of TNX deWcient patients. Our data could serve as
a starting point to investigate the function of individ-
ual domains in the context of the physiological TNX
Fig. 6 Binding of FNIII29–30 to ECM proteins. Recombinant
FNIII29–30 (without fusion tag) binds to collagen types I, III and
V and to TE essentially in the same manner as the MBP fusion
proteins containing FNIII29. BSA is used as a control for back-
ground staining (7.5 g/ml)
Fig. 7 TNX FNIII29 aVects collagen Wbrillogenesis. a TNX
FNIII29 has a dose dependent eVect on the Wbrillogenesis rate of
bovine collagen type I in a turbidimetric assay. At a concentration
of 48 g/ml MBP–FNIII29 the Wbrillogenesis rate in the lateral
growth phase is signiWcantly increased. At a concentration of
24 g/ml MBP–FNIII29 does not signiWcantly inXuence the later-
al growth phase, although at both 24 and 48 g/ml the lag phase is
shortened. MBP and BSA served as a negative control. The
curves of BSA and 4.8 g/ml MBP–FNIII29 overlapped with the
MBP curve and have been omitted for reasons of clarity. b Com-
parison of TNX FNIII29 levels in the supernatant of pelleted
insoluble collagen Wbrils compared to controls. DiVerences of
TNX FNIII29 concentration in the supernatant reXect the
amount of TNX FNIII29 bound to the pelleted insoluble collagen
Wbrils
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molecules, like the 450 kDa tissue form or the various
serum forms. Further investigation of the role of TNX
in extracellular matrix assembly and stability will
increase our knowledge of connective tissue biology
and will oVer a molecular explanation for the pheno-
type of TNX deWcient patients.
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ABSTRACT 
Tenascin-X (TNX) is a large extracellular 
matrix protein expressed in a variety of 
tissues including skin, joints and blood 
vessels. Deficiency of TNX causes a 
recessive form of Ehlers-Danlos syndrome 
characterized by joint hypermobility, skin 
fragility and hyperextensible skin.  
Recently we have demonstrated that TNX 
binds to collagen type XII, a fibril 
associated collagen that co-localizes with 
TNX in a number of tissues. In this report 
we identify domains in TNX and collagen 
type XII responsible for this interaction. 
 
INTRODUCTION 
TNX is a large 450 kDa extracellular matrix 
(ECM) glycoprotein composed of EGF like-
repeats, fibronectin type III (FNIII) repeats 
and a C-terminal fibrinogen domain 
(FbgX). TNX is expressed in several 
tissues such as skin, muscle and blood 
vessels [1-4]. Complete deficiency of TNX 
in humans leads to a recessive form of 
Ehlers Danlos syndrome and TNX 
haploinsufficiency is a cause of 
hypermobility type Ehlers Danlos 
syndrome. The skin of TNX deficient 
patients is markedly lax with poor recoil 
properties and shows easy bruising [5-9]. 
Recently we have demonstrated an 
interaction between TNX and collagen 
type XII [10]. Collagen type XII is a fibril 
associated collagen composed of two 
short collagen domains, which are flanked 
and interrupted by three non-collagenous 
domains (NC). The NC3 domain is the 
largest domain containing several von 
Willebrand factor type A domains (vWA), 
FNIII repeats and a thrombospondin N-
terminal like domain (TSPN). Alternative 
splicing in the NC3 and NC1 domain 
results in four different collagen XII 
isotypes [10]. Collagen type XII is thought 
to act as a linker between collagen fibrils, 
although, until recently the mechanism by 
which this is accomplished was 
incompletely understood. In a previous 
report we demonstrated co-localization of 
collagen type XII and TNX in skin and 
muscle. Furthermore we showed binding 
of TNX to collagen type XII. In this report 
we identify sites in both collagen type XII 
and TNX responsible for the interaction 
between these proteins. 
 
MATERIALS AND METHODS 
 
Proteins and antibodies 
TNX recombinant proteins were obtained 
as previously described [11;12] Briefly, 
sequences encoding for TNX domains 
were cloned into pMal-c2X (Westburg 
B.V., Leusden, NL) and pET28(a)+ 
plasmids (Brunschwig Chemie B.V., 
Amsterdam, NL). Sequences were verified 
by dideoxy sequencing with a 3730 DNA 
analyzer (Applied Biosystems, Nieuwekerk 
a/d IJssel, NL). The following TNX 
fragments were obtained from E.coli BL21 
cells (Invitrogen, Breda, NL) as maltose 
binding protein (MBP) fusion proteins: 
MBP-FNIII27-28, MBP-FNIII28-29, MBP-
FNIII29, MBP-FNIII29-30, MBP-FNIII30-
31, MBP-FbgX. FNIII27-32 was obtained 
as 6xHIS tagged recombinant protein 
(HIS-FNIII27-32 from E.coli TOP10F’ cells 
(Invitrogen, Breda, NL) according to the 
manufacturer’s instructions. A 100 kDa C-
terminal recombinant TNX protein, 
containing six FNIII repeats (FNIII27-32) 
and the fibrinogen domain, encoded by a 
2.7 kb TNX sequence has previously been 
described by Tee et al. [13;14]. Antibodies 
against human TNX were obtained as 
previously described [11;12].  
For cloning of full-length collagen 
XIIA and B (short isoform) and collagen XII 
fragments, primers were designed 
according to GenBankTM accession 
number NM_007730. RT-PCR on total 
RNA of mouse E15.5 was performed as 
previously described by us [15]. The 
following fragments were amplified 
separately by RT-PCR with specific 
primers and ligated into a modified pBK II 
vector and sequenced: the 3rd vWA (von 
Willibrand factor A) domain to the 13th 
FNIII domain (primers: M854, M894, 
termed N-XIIB), 14th FNIII domain to 4th 
vWA domain (primers: P143, P144; 
termed middle fragment), TSPN domain to 
NC1 domain (primers: P3, P8; termed C-
XIIB) (see table 1 for a list of PCR 
primers). For eukaryotic expression the N-
XIIB and C-XIIB fragments alone were 
ligated into a modified pCEB-Pu vector. To 
assemble collagen type XIIB the N-XIIB 
and C-XIIB fragments were ligated 
together into a modified pCEB-Pu vector 
and the middle fragment was inserted 
through the internal restriction sites Bsp EI 
and Nde I. For the full-length collagen type 
XIIA the N-XIIB fragment from the 1st vWA 
domain to the 8th FNIII domain was 
amplified as described above (primers: 
P145, P146) and introduced into the 
collagen XIIB construct by using  the 
internal restriction site Nsi I. The collagen 
type XII TSPN domain was amplified using 
the primer pair P3 - P581, the collagen 
type XII FNIII6-8 domains were amplified 
with the primer pair M920 - M921, and 
both were cloned into a modified pET 
vector for bacterial expression. 
The cDNAs of full length Col XIIA 
and B and the C-XIIB and N-XIIB 
fragments ligated into the pCEB-Pu vector 
containing a His8 tag were used to 
transfect 293-EBNA cells (Invitrogen) 
using FuGENE 6 reagent (Roche, 
Mannheim, DE) according to the 
manufacturer’s instructions. Stable 
transfected cells were selected with 
puromycin (1.25 µg/ml). The highest 
protein-producing clones were expanded. 
For large-scale protein production the cells 
were cultivated in serum free DMEM/F12 
with GlutamaxTM (Gibco, Karlsruhe, DE) 
supplemented with 250 µM L-ascorbic acid 
and 450 µM L-ascorbic acid 2-phosphate. 
For each construct three litres of 
conditioned media were collected, filtrated 
and supplemented with 1 mM Pefablock 
(Merck, Darmstadt, DE), 10% Na2HPO4 
and 0,2% Tween-20 (Sigma, Munich, DE). 
The supernatant was applied onto a Ni 6 
Fast Flow column (GE Healthcare, 
Munich, DE). The recombinant protein was 
eluted by stepwise increasing 
concentrations of imidazole (5-250 mM) in 
TBS (20 mM Tris-HCl, 150 mM NaCl, pH 
8.0) and dialysed against TBS. Bacterial 
expression in BL21 cells and purification 
was performed as described previously 
[10]. 
BSA and (Sigma-Aldrich Chemie 
B.V., Zwijndrecht, NL) MBP (Westburg 
B.V., Leusden, NL) were used as a 
negative control. Monoclonal antibodies 
specific for MBP (Westburg B.V., Leusden, 
NL) and previously described TNX and 
collagen type XII antibodies [10-12] were 
used for detection of TNX and collagen 
type XII in our solid-phase assays. 
 
Solid phase binding assays 
Ninety-six well microtiter plates (Greiner 
Bio-One B.V., Alphen aan den Rijn, NL) 
were coated overnight at 4°C with collagen 
type XII or TNX diluted in PBS. All further 
incubation steps were performed at 37°C. 
Wells were washed with PBS containing 
0.05% Tween-20 (T-PBS) after each 
incubation step. After coating wells were 
saturated with 1% BSA in T-PBS for 2 h.  
Binding of TNX domains (soluble 
phase) to collagen type XII and 
recombinant collagen type XII fragments 
(solid phase) was performed essentially as 
previously described for other ECM 
components [11]. Briefly wells were 
incubated with recombinant TNX domains 
for 1 h.  After incubation with 100 kDa TNX 
wells were incubated with rabbit antibodies 
against HIS-TNX-FNIII27-32. Incubation 
with TNX MBP fusion proteins was 
followed by incubation with a mouse 
monoclonal antibody against MBP for 1 h. 
Thereafter, wells were incubated with 
  
biotinylated anti rabbit (Vector 
Laboratories Inc., Burlingame, CA) or 
biotinylated anti mouse IgG (vectastain kit, 
Brunschwig Chemie, Amsterdam, NL) 
respectively for 1h followed by a 45 min 
incubation with an avidin-biotin-horse 
radish peroxidase mixture (vectastain kit, 
Brunschwig Chemie, Amsterdam, NL). 
Bound peroxidase was detected with o-
phenylenediamine dihydrochlorid (Perbio 
Science Nederland B.V., Etten-Leur, NL) 
and the absorbance read at 490 nm. All 
antibodies and TNX proteins were diluted 
in T-PBS containing 0.1% BSA. BSA was 
used as negative control, MBP for 
baseline correction.  
Binding of collagen type XII 
(soluble phase) to TNX domains (solid 
phase) was performed essentially as 
described above. Briefly wells were 
incubated with collagen type XII and 
recombinant collagen type XII fragments 
for 1 h, followed by incubation with a 
previously described collagen XII antibody 
(KR33). Detection was performed with 
HRP linked anti-rabbit antibody (Cell 
Signalling, Berverly, US) and TMB 
substrate (Perbio Science Nederland B.V., 
Etten-Leur, NL). The reaction was stopped 
with 4 M H2SO4, absorbance was read at 
450 nm. All antibodies and collagen type 
XII proteins were diluted in T-PBS 
containing 0.1% BSA. BSA was used as 
negative control.  
 
Surface plasmon resonance 
spectroscopy 
Surface plasmon resonance spectroscopy 
was performed using a BIAcore 2000 
(BIAcore AB) system. For measurement of 
protein-protein interactions full-length 
collagen type XIIA or collagen type XII 
fragments were coupled in 25 mM sodium 
acetate, pH 4.5 with a flow rate of 5 µl/min 
to a CM5 chip. The chip was previously 
activated with N-hydroxysuccinimide and 
1-ethyl-3-(3-dimethylaminopropyl) carbodi-
imide hydrochloride. After coupling the 
required amount of protein (~ 1000 RU), 
unbound reactive groups were saturated 
with 1 M ethanolamine hydrochloride, pH 
8.5. Experiments were carried out using 
serial dilutions (1000 nM, 500 nM, 250 nM, 
125 nM, 62.5 nM and 31.25 nM) of the 
different TNX fragments diluted in running
 
 
 
Figure 1: Schematic overview of collagen XII and recombinant collagen XII fragments. 
Murine collagen XIIA (mCol XIIA), the short isoform of collagen type XII (mCol XIIB), recombinant collagen type 
XII fragments; C-XIIB, N-XIIB, thrombospondin N-terminal domain (TSPN) and FNIII6-8 are displayed 
schematically. 
  
Table 1: List of PCR primers for collagen type XII constructs. 
 
name fw/rev sequence 
M854 fw caagctagcgaagggatggattgtctcaccagag 
M894 rev caagcggccgcttaaccttctgtatagaccggaacc 
M920 fw aatgctagccttgaagaacgtggctcacc 
M921 rev tttggatccttaagaagatagaaatggtgtcac 
P3 fw aaagctagccaggatggctacacatcaccagg 
P8 rev ttgggatccttagccggaacctggatagccttgc 
P143 fw aaagctagcgcatatgacacaacccggc 
P144 rev caagcggccgcttaagatccggattccaaagagac 
P145 fw caagctagcgaagacccaccttccgacttg 
P146 rev ttgctcgagttacacatgcatagtggtggggcc 
P581 rev ttgggatccttagtctctactggtccacac 
 
fw: forward primer; rev: reverse primer 
 
buffer (20 mM hepes; 150 mM NaCl; 2 mM 
CaCl2; 0.005% Tween-20). The analyte 
was passed over the sensor chip with a 
constant flow rate of 30 µl/min for 120 sec, 
dissociation was measured over 300 sec. 
Fittings of the data, overlay plots and 
calculation of Kd values were perfomed 
with BIAevaluation software 3.2 estimating 
a 1:1 model. 
 
SDS-PAGE analysis 
Proteins were loaded onto 12% BIS-TRIS 
gels (Invitrogen, Breda, NL). Gel 
electrophoresis was carried out using the 
NuPAGE system according to the 
manufacturer’s instructions (Invitrogen, 
Breda, NL). To analyze protein purity gels 
were stained using coomassie brilliant 
blue R250 (Brunschwig Chemie, 
Amsterdam, NL).  
 
RESULTS 
 
Binding of C-terminal 100 kDa TNX to 
collagen type XII  
We previously showed interaction of the 
NC3 domain of collagen type XII to TNX 
[10]. As a first approach to identify the 
domain(s) in TNX responsible for binding 
to collagen XII we performed solid phase 
assays to test binding of a recombinant C-
terminal 100 kDa TNX fragment [13;14] 
(soluble phase) to collagen type XII, 
recombinant collagen type XII fragments 
and BSA (immobilized substrates). The 
collagen type XII proteins are shown 
schematically in figure 1. The TNX 
proteins used in this study have been 
previously described [11-14]. Figure 2 
shows that C-terminal 100 kDa TNX binds 
dose dependently to collagen XIIA, the 
short isoform of collagen type XII (XIIB) 
and the C-XIIB fragment. Binding to BSA, 
which served as a negative control, the N-
XIIB fragment and FNIII6-8 of collagen 
type XII was absent. 
 
Identification of the domain in TNX that 
interacts with collagen type XII 
To identify the sequences in TNX 
responsible for binding to collagen XII we 
subcloned and expressed a number of 
fragments from the C-terminal 100 kDa 
TNX protein as previously described 
[11;12]. All TNX recombinant proteins 
containing the FNIII29 repeat showed
 
  
Figure 2: Binding of recombinant C-
terminal 100 kDa TNX to full length -
and fragments of collagen type XII. 
TNX binds dose dependently to full 
length (XIIA) -and the short isoform 
(XIIB) of collagen type XII. Binding to 
the C-XIIB fragment is observed, 
although saturation is not reached. 
Binding to BSA (solid phase), which 
served as a negative control, was 
absent. Proteins in the solid phase are 
marked in the legend. 
 
  
 Figure 3: Binding of 
recombinant proteins 
containing TNX FNIII29 to 
collagen type XII. 
(a) Recombinant TNX proteins 
containing FNIII 29 bind dose 
dependently to full length collagen 
type XII. Data for MBPFNIII29-30, 
FNIII30-31 and MBP-FbgX are not 
shown for reasons of clarity. No 
binding is observed for TNX 
recombinant proteins that lack 
FNIII29 for BSA. Proteins in the 
soluble phase are marked in the 
legend. (b) Recombinant TNX 
proteins containing FNIII 29 bind 
dose dependently to the C-XIIB 
fragment, a C-terminal fragment of 
collagen type XII. Data for 
MBPFNIII29-30, FNIII30-31 and 
MBP-FbgX are not shown for 
reasons of clarity. No binding is 
observed for TNX recombinant 
proteins that lack FNIII29 and for 
BSA. Proteins in the soluble phase 
are marked in the legend. 
 
 
dose dependent binding to collagen type 
XII (fig. 3a, shown for collagen type XIIA) 
and C-XIIB fragment (fig. 3b). No binding 
was observed for repeats FNIII27-28, 
FNIII30-31, the FbgX domain as was also 
the case for BSA. For reasons of clarity 
only the data for MBP- FNIII27-28, 
FNIII28-29 and FNIII29 of TNX and BSA 
are shown. To verify the results, 
interaction of collagen type XIIA and XIIB 
(soluble phase) to HIS-FNIII27-32 (solid 
phase) and MBP-FNIII29 (solid phase) 
was investigated. Binding of collagen type 
XIIA and XIIB to these recombinant TNX 
fragments was found (data not shown), 
confirming the previous results.  
 To validate the results, surface 
plasmon resonance spectroscopy was 
performed and the associations and 
dissociations of the obtained binding 
curves were analyzed in a Langmuir 1:1 
binding model (fig. 4). The apparent Kd 
values for MBP-FNIII29 as soluble partner 
were 8.3 x 10-9 M for collagen type XIIA 
and 1.3 x 10-8 M for C-XIIB fragment. 
These are comparable to the Kd values for 
HIS-FNIII27-32 as soluble partner; 6.5 x 
10-9 M for collagen type XIIA and 8.8 x 10-9 
M for C-XIIB fragment. The Kd value for C-
terminal 100 kDa TNX as soluble partner 
for collagen type XIIA is 4.8 x 10-9 M (data 
not shown). MBP-FNIII27-28 and MBP 
(not shown) were used as negative 
controls and no binding to collagen type 
XII or the C-XIIB fragment was observed in 
either case. Furthermore, no binding of 
TNX recombinant proteins to N-XIIB was 
found (data not shown). 
 
Identification of the domain in collagen 
type XII that interacts with FNIII repeat 
29 of TNX  
We previously showed interaction of the 
NC3 domain of collagen type XII to TNX 
[10]. We showed binding of the C-XIIB 
fragment, consisting of TSPN, NC1, NC2 
and collageneous domains, to FNIII29 of 
TNX.
  
 
Figure 4: Surface plasmon resonance spectroscopy confirms binding of FNIII 29 to collagen type XII. 
MBP-FNIII29 and HIS-FNIII27-32 bind to collagen type XIIA and the C-XIIB fragment. MBP-FNIII27-28 and MBP 
(not shown) were used as negative controls and no binding to collagen type XII or the C-XIIB fragment was 
observed in either case. TNX recombinant proteins were used as soluble analytes and the amount of interacting 
analyte (1000, 500, 250, 125, 62.5 nM) was monitored by measuring the variation of the plasmon resonance 
angle as a function of time and expressed in terms of response units. The background signal has been subtracted 
from each curve; the curves are shown in ascending order depending on the analyte concentration used. Fitting 
and overlay plots were performed with BIAevaluation software version 3.2. The continuous black lines represent 
the fitted curves. 
 
The TSPN domain is part of the NC3 
domain, suggesting this domain is 
responsible for the binding to FNIII29 of 
TNX. The TSPN of collagen type XII was 
expressed as recombinant protein and 
binding to FNIII29 was investigated using 
surface plasmon resonance spectroscopy. 
The TSPN domain alone was able to bind 
to the FNIII29 repeat of TNX as shown in 
figure 5. The Kd value for the TSPN 
domain is 6.3 x 10-9 M for HIS-FNIII27-32 
as soluble partner and 8.5 x 10-9 M for 
MBP-FNIII29 as soluble partner. 
Furthermore, collagenase treatment of 
collagen type XIIA/B did not result in a 
decrease of binding to FNIII29 of TNX 
(data not shown) as had also been 
previously shown for full length TNX [10].
 
  
 
 
Figure 5: Binding of the TSPN domain of collagen type XII to FNIII29 of TNX. 
Binding of the TSPN domain of collagen type XII to MBP-FNIII29 and HIS-FNIII27-32 of TNX is shown by surface 
plasmon resonance spectroscopy. MBP-FNIII27-28 was used as negative control and no binding to the TSPN 
domain of collagen type XII was detected. TNX recombinant proteins were used as soluble analytes and the 
amount of interacting analyte (1000, 500, 250, 125, 62.5 nM) was monitored by measuring the variation of the 
plasmon resonance angle as a function of time and expressed in terms of response units. The background signal 
has been subtracted from each curve; the curves are shown in ascending order depending on the analyte 
concentration used. Fitting and overlay plots were performed with BIAevaluation software version 3.2. The 
continuous black lines represent the fitted curves. 
 
DISCUSSION 
We identified domains in TNX and 
collagen type XII which are responsible for 
the interaction between these two 
proteins. In a previous study we linked the 
interaction for collagen type XII with TNX 
to the large NC3 domain of collagen type 
XII with the use of collagenase treated 
collagen type XII [10]. The NC3 domain 
contains, amongst vWA domains and FNIII 
repeats, a TSPN domain. In this study we 
demonstrated that the TSPN domain of 
collagen type XII is able to bind to the 
FNIII29 of TNX. We previously identified 
binding of elastin and collagen types I, III 
and V to FNIII29 of TNX [11]. Although 
collagen type V harbors a TSPN domain, 
collagen type I, III and elastin lack such a 
domain. This suggest that there could be 
multiple interaction sites in FNIII29 of TNX 
or that FNIII29 has more general binding 
properties allowing it to interact with a 
number of amino acid moieties or 
structural conformations. Further 
investigation into the domain structure of 
FNIII29 of TNX including generation of 
mutant FNIII29 recombinant proteins could 
provide answers to these questions. 
 The existence of multiple 
collagen type XII – TNX interaction sites 
cannot be excluded by this study. 
However, the discovery of an interaction 
between the TSPN domain of collagen 
type XII and FNIII29 of TNX provides 
novel biochemical evidence for collagen 
type XII and TNX as interaction partners 
through the binding sites in these two 
domains. Further investigations into the 
role of TNX and collagen type XII in 
extracellular matrix stability will increase 
our knowledge of connective tissue 
biology. Currently the genetic causes for 
the Ehlers-Danlos syndrome are known in 
approximately 50% of the cases. Our data 
could act as a starting point for the 
identification of novel genetic cause for the 
Ehlers-Danlos syndrome. Collagen type 
XII, considering the interaction with TNX, 
is a likely candidate gene for this disease.  
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CHAPTER 7 
 
Identification and characterization of multiple species of 
tenascin-X in human serum 
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Figure S1. Amino acid sequence coverage of the 75 and 140-150 kDa species. 
Peptide amino acid sequences found after trypsinization and analysis by MS/MS are underlined (Figure expanded 
from Fig. 4). (a) The covered peptide amino acid sequences by MS/MS suggest a molecular weight (MW) of at 
least 70 kDa (without glycosylation) for the 75 kDa species. The most N-terminal peptide amino acid sequence is 
located near the C-terminus of FNIII28 (the amino acid sequences for FNIII28 and FNIII29 are designated by 
horizontal brackets) b). Sequence coverage by MS/MS of the 140-150 kDa TNX species revealed peptide amino 
acid sequences which align mostly with the C-terminal part of TNX. Due to the homology between FNIII repeats 
three peptide sequences can be aligned on multiple positions in the TNX sequence (the most C-terminal 
occurrences are marked bold, the amino acid sequences for FNIII24 and FNIII28 are designated by horizontal 
brackets). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 8 
 
SUMMARY, DISCUSSION AND FUTURE PROSPECTS 
SUMMARY, GENERAL DISCUSSION AND FUTURE 
PROSPECTS 
 
INFLUENCE OF TENASCIN-X ON 
MATRIX DEVELOPMENT, MATURATION 
AND REMODELING 
One of the objectives of the investigations 
described in this thesis was to study the 
role of tenascin-X (TNX) in the 
development, maturation and remodeling 
of the extracellular matrix (ECM). In 1997 
Burch et al. described a reduced collagen 
density in the skin of the TNX deficient 
index patient [1]. Two groups 
independently generated TNX deficient 
mice in order to gain more insight into the 
function of TNX. Matsumoto et al. were the 
first to publish data on a TNX KO mouse 
model [2]. According to Matsumoto et al. 
TNX KO mice appeared healthy and had 
no gross abnormalities, however tumor 
invasion and metastasis appeared 
increased [2]. Mao et al. described a skin 
phenotype in the TNX KO mice. The skin 
of the TNX KO mice was markedly lax and 
fragile, supposedly induced by a disturbed 
collagen deposition [3]. Zweers et al. 
quantified the reduction in collagen density 
in a group of TNX deficient patients [4]. 
However, the collagen reduction in the 
skin of TNX KO mice is a matter of debate. 
Mao et al showed a reduction in density of 
collagen in skin and claimed similar results 
in tail and Achilles tendon. Mao et al. 
suggested that TNX is essential for 
collagen deposition into the ECM based 
on observations made in cultured dermal 
fibroblasts [3]. However, they incorrectly 
stated that TNX is not expressed in fetal 
rodent skin referring to a study by Burch et 
al. [5], where skin was not investigated 
and a study by Matsumoto et al., which did 
show expression of TNX in the dermis of 
E15.5 mice [6]. Mao et al. did not 
investigate TNX in fetal rodent 
development. In chapter 2 we 
investigated the role of TNX in dermal 
development. We found that TNX KO skin 
is already significantly weaker compared 
to wild type (WT) mice at the earliest 
measurable time point (two weeks post 
partum). The difference in skin strength 
between TNX KO and WT is larger in adult 
mice compared to young mice. However, 
as outlined in chapters 2 and 3 we found 
no difference in collagen distribution or 
density for total collagen or the fibrillar 
collagens type I, III and V nor in the 
amount of collagen as measured by 
hydroxyproline content. Independent 
studies by Minamitani et al. [7] and 
Matsumoto et al. [8] showed no difference 
in density or shape of collagen fibrils in 
sciatic nerves or dermis as evaluated by 
EM, although there appears to be an 
increase in size variation in dermal 
collagen fibrils [3;7].  Even more 
interestingly we found protein expression 
of fibrillar collagens type I, III and V to 
precede TNX both in dermal development 
as well as in matrix remodeling after skin 
injury (chapters 2 and 3). This suggests 
TNX is not involved in the initial deposition 
of collagen in the ECM of the dermis. This 
theory is supported by the observation that 
no obvious differences in density or 
localization of the fibrillar collagens in 
uterus between TNX KO and WT mice 
were found, in spite of constant 
remodeling of the connective tissue in the 
uterus during the menstrual cycle and 
during pregnancy (chapter 3). It must be 
noted that Mao et al. used littermates from 
a heterogeneous background in their 
studies, while our studies and those of the 
group of Matsumoto were performed on a 
more homogenous background (C57B6 
mice), offering a possible explanation for 
the discrepancies in the studies. Another 
point of interest is the difference of TNX 
deficiency on collagen density in humans 
and mice. The relative collagen density in 
TNX deficient patients, quantified by 
Elastica-von-Gieson stained sections, 
appears reduced [4]. This is in contrast 
with observations made by us (chapters 2 
and 3) and Minamitani et al. [7] in the 
dermis of mice. It seems unlikely that TNX, 
which is very similar in mouse and human, 
would have different functions in those 
species. However, due to species 
differences the effects of TNX deficiency 
could differ between the species. The TNX 
KO mice appears to have a much milder 
phenotype compared to TNX deficient 
patients as they do not exhibit signs of 
hypermobility or lax ligaments (chapter 2), 
nor do they exhibit a high frequency of 
associated GU and rectal abnormalities 
(chapter 3) or other complications as 
observed in TNX deficient patients 
(chapter 3) [1;9;10]. 
Another alteration in the connective 
tissue of TNX deficient patients concerns 
the elastic fibers. The index patient 
showed abnormal elastic bodies beneath 
the dermal-epidermal junction [1]. Zweers 
et al. investigated this in a group of TNX 
deficient patients and observed that elastic 
fiber abnormalities are associated with 
TNX deficiency. Elastic fibers in these 
patients are shorter and contain fewer 
branches compared to age matched 
controls. EM revealed fragmented elastic 
fibers and aggregates of microfibrils and 
elastin [4]. Interestingly, elastic fiber 
abnormalities are found in the dermis of 
mice only after 3-6 months of age, 
suggesting a role for TNX in the stability or 
maintenance of elastic fibers. After 3-6 
months there is an increase in elastin 
reactive material in the dermis of these 
mice as observed by immunostaining and 
elastin aggregates can be observed 
through EM. Also fibers in the TNX KO 
mice appear bigger compared to WT mice, 
though the shape appears normal. No 
elastic fiber abnormalities are found in the 
uterus and aorta of mice or in the mitral 
valve of a TNX deficient patient (chapter 2 
and 4) [11] in spite of TNX expression in 
these tissues, suggesting the effects of 
TNX deficiency on elastic fibers are tissue 
specific. 
Puzzling however, is the 
observation that despite the apparent lack 
of pronounced differences in collagen 
content and the late onset of elastic fiber 
abnormalities in the skin of TNX KO and 
WT mice the skin strength of the TNX KO 
mouse is markedly reduced compared to 
WT mice even at a young age (chapters 2 
and 3) [3]. As soon as TNX protein 
expression starts, colocalisation with 
dermal fibrillar collagens I, III and V can be 
observed, suggesting TNX could play a 
role in matrix maturation or stability 
(chapters 2 and 3). Alternatively, TNX 
deficiency could lead to an upregulation of 
matrix degrading enzymes. It has been 
shown that lack of TNX in the dermis 
appears to facilitate tumor progression in 
mice and MeLiM swine [2;12;13], possibly 
due to an increase in matrix 
metalloproteinase (MMP) expression or 
adhesive defects in TNX null fibroblasts 
[2;13-15].  However, several questions 
regarding the interpretation of these 
studies remain. The expression is shown 
on mRNA level for most MMPs, only for 
MMP-2 an increase in active form is 
shown. Fibroblast cultures of TNX KO 
mice and WT mice show no differences in 
MMP activity, unless in the presence of a 
collagen lattice.  A co-culture of fibroblasts 
with B16-BL6 melanoma cells even 
showed a decrease in the MMP activity in 
TNX KO fibroblasts compared to WT 
fibroblasts. Furthermore, data from 
TNX/TNC double KO mice are difficult to 
interpret since only the tumor size in TNX 
KO mice is increased, while tumors in the 
TNC KO and TNX/TNC double KO mice 
are equal to WT, yet survival in all tenascin 
KO mice is decreased. Interestingly, while 
an increase of pro-MMP-9 was shown in 
TNX KO mice, MMP-9 mRNA expression 
is increased in all tenascin KO mice. Most 
importantly however, no qualitative 
differences in collagen fibrils or the 
basement membrane are observed on the 
ultrastructural level in TNX KO mice 
[2;7;13-15]. Abnormalities in elastic fibers 
appear only in adult mice (as of 3-6 
months) and are not yet appreciatable in 
young mice (<2 months). All investigated 
TNX deficient patients are well into 
adulthood and the collagen density and 
abnormal elastic fibers could not be 
investigated in young individuals. Although 
it cannot be excluded that a slow 
degradation of the ECM by an 
upregulation MMP could account for these 
changes it is more plausible that TNX itself 
could stabilize the matrix by interacting 
with various ECM components 
strengthening the ECM and making it less 
susceptible to breakdown. TNX could also 
play a role in the maturation and thus the 
quality of elastic fibers and collagen.  
 
 
INTERACTIONS OF TNX WITH ECM 
COMPONENTS 
In order to play a role in the stabilization or 
maturation of the ECM TNX must 
colocalize and interact with other ECM 
components. We have shown that TNX 
starts to colocalize with collagen types I, III 
and V and elastin in the dermis during 
development after the intial deposition of 
these proteins (chapter 2).  In chapter 5 
we show binding to collagen types I, III 
and V and elastin and identify interaction 
sites in the C-terminus of TNX. We found 
binding of fibronectin type III repeat 29 
(FNIII29) of human TNX to collagen types 
I, III, V and elastin. The fibrinogen domain 
of TNX showed binding to elastin and not 
to any other of the ECM components 
tested. Furthermore, in chapter 6 we show 
binding of TNX to collagen type XII, a fibril 
associated collagen (FACIT) thought to 
link collagen fibrils together. We show that 
the TSPN-like domain in the non-
collagenous region 3 of COLXII and the 
FNIII29 of TNX are able to interact with 
each other. It has become increasingly 
clear that TNX can interact with a large 
number of ECM components such as; 
heparin, decorin, elastin and collagen 
types I, III, V, XII, XIV (chapter 5 and 6) 
[6;7;16-19]. Furthermore, cells are able to 
adhere to TNX, suggesting a function for 
TNX as linker between cells and the ECM 
[20;21]. Here we propose a model, as 
depicted in figure 1, in which TNX acts as 
a linker between various components of 
the ECM and to cells, thus stabilizing the 
extracellular matrix.  
 
TNX AS A COMPONENT OF SERUM 
Previously, a 140 kDa TNX species was 
identified in human serum. The 140 kDa 
TNX serum species is recognized by an 
antibody directed against the C-terminus 
of TNX however,  further details were not 
known [10]. A sandwich ELISA was 
developed by Schalkwijk et al. [10] to 
determine the relative concentration of 
TNX in serum for screening of TNX 
deficient patients and TNX heterozygosis 
[9;10;22].  The same ELISA was used by 
Zweers et al. to show that an elevated 
level of serum TNX is a risk indicator for 
abdominal aorta aneurysm. During the 
research on TNX in human serum we 
developed and validated TNX ELISAs, 
which incorporated avian antibodies to 
avoid the effects of heterophilic antibodies. 
The ELISAs could be used to investigate 
serum TNX concentrations in pathological 
conditions other than EDS. In chapter 7 
we investigated serum TNX using newly 
generated and existing antibodies against 
the C-and N-terminus of TNX and mass 
spectrometry. Interestingly we discovered 
multiple species of TNX in serum, some of 
which surprisingly were not discovered in 
previous studies. Furthermore we found 
that during storage of serum samples the 
measured serum TNX concentration would 
decrease. We also discovered a 
correlation between serum TNX levels and 
age, as it appears young children have 
elevated serum levels compared to adults. 
Recently Matsumoto et al. described 
serum forms of TNX in mice. They found 
one predominant species of 200 kDa and 
showed that a 200 kDa TNX species was 
formed from full length TNX after 
incubation with spleen homogenate at 
acidic pH. They speculated that other TNX 
species were proteolytic intermediate 
products derived from full length TNX [23]. 
No full human length TNX was available to 
study the proteolytic cleavage products of 
human TNX. Although a TNX species of 
approximately 200 kDa appears present in 
human serum, the two predominant 
human serum TNX species are 
approximately 75 kDa and 140-150 kDa. 
Unfortunately, the exact N-terminus of 
neither species could be established 
making it difficult to make any assumptions 
on cleavage sites. However, the 75 kDa 
form is very similar to the adrenal specific 
short TNX isoform (XB-S) [24]. Although 
the 75 kDa TNX species is still present in 
serum of patients with a double adrenal 
ectomy, it cannot be excluded that XB-S is 
expressed and excreted by cells other 
than adrenal gland cells since only 
adrenal, muscle, liver, brain, kidney and 
heart tissue were examined [24]. In 
conclusion we have shown that, there are 
multiple TNX species in serum and TNX 
concentration in serum is dependant on 
storage and patient age. There are two 
predominant    C-terminal    TNX   species,  
 
 
 
Figure 1: A model of stabilization of the ECM by TNX. 
TNX links together various components of the ECM either as a trimer (#4a) or monomer (#4b). TNX can link 
collagen fibrils containing collagen I, III or V (#2) together directly, through decorin () or FACIT collagens such 
as collagen XII (#5). Furthermore TNX could link collagen bundles to cells (#1) or elastic fibers (#3), thus acting 
as an “extracellular glue”. 
 
 
which are to have some biological activity 
as they are able to bind to tropoelastin 
(chapter 7).  
 
CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
TNX was the first tenascin of which 
deficiency could be linked to a human 
pathological condition. The TNX KO 
mouse was the first tenascin KO mouse 
with an overt phenotype.  During the 
course of this thesis it became apparent 
that there are several discrepancies 
between studies regarding the changes in 
tissue morphology associated with TNX 
deficiency. In this thesis we describe a 
major role for TNX as stabilizer of the 
ECM, acting as a linker between collagen 
fibrils, elastic fibers and cells.  
 We provide a basis for the 
research on serum TNX levels in 
pathological conditions, in which our 
observations should act as guidelines. Our 
observations on the interaction between 
collagen type I, III, V and XII and elastin 
with TNX provides a basis for further 
research. Interestingly FNIII repeat 
number 29 of human TNX is able to bind 
to a large number of ECM molecules. This 
repeat differs from other FNIII repeats in 
TNX because it contains an additional, 
unique stretch of amino acids, as is shown 
in figure 2 for FNIII27 to 31. Murine 
FNIII26 of TNX and bovine FNIII27 of TNX 
match human FNIII29 of TNX and also 
contain this additional stretch of amino 
acids, suggesting a similar biological 
function. Mutational analysis of repeat 
FNIII29 should reveal more details on the 
amino acid sequence responsible for the 
interaction. This could result in 
development of FNIII29 derived peptides 
that could possibly be used as a research 
tool or as a therapeutic application in 
matrix biology and wound healing.  
 A second important starting point 
for future research is collagen type XII as 
a candidate gene for connective tissue 
diseases such as the Ehlers-Danlos 
syndrome. Taken together I conclude that 
the work described in this thesis will open 
up new avenues in basic and applied 
biology of TNX.  
 
 
 
Figure 2: Alignment of human TNX FNIII repeats. 
Alignment of FNIII29 of human TNX to FNIII repeats tested in chapters 5 and 6 (CLUSTAL W (1.83) multiple 
sequence alignment). An arrow indicates a unique stretch of extra amino acids, not found in other FNIII repeats in 
TNX.  
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NEDERLANDSE SAMENVATTING 
 
 
De extracellulaire matrix is de materie 
tussen cellen en is essentieel voor de 
ontwikkeling, vorm en instandhouding van 
ons lichaam. De extracellulaire matrix 
bestaat voornamelijk uit collageen 
bundels, elastische vezels, glycoproteïnen 
(proteïnen = eiwitten) en proteoglycanen. 
Afwijkingen in de opbouw en 
samenstelling van de extracellulaire matrix 
kunnen leiden tot het ontstaan van diverse 
ziekten. Een van de bestanddelen van de 
extracellulaire matrix is het eiwit tenascine-
X. In samenwerking met Amerikaanse 
wetenschappers is op de afdeling 
dermatologie van het Radboud ziekenhuis 
enkele jaren geleden aangetoond dat de 
afwezigheid van dit eiwit in een mens leidt 
tot een vorm van het Ehlers-Danlos 
syndroom. Deze erfelijke 
bindweefselaandoening uit zich in 
overbeweeglijke gewrichten en een sterk 
uitrekbare, fragiele huid. Wanneer de huid 
van deze mensen onder de microscoop 
wordt bekeken, hebben zij een 
verminderde dichtheid van collageen en er 
zijn misvormde elastische vezels in de 
lederhuid (= dermis). Om te begrijpen hoe 
afwezigheid van tenascine-X tot deze 
afwijkingen leidt, is het belangrijk om de 
veranderingen in de extracellulaire matrix 
te volgen. Deze studies zijn vanwege 
medisch-ethische en praktische redenen 
niet in mensen uitvoerbaar. Om toch 
onderzoek te kunnen doen hebben we 
gebruik gemaakt van een tenascine-X 
“knockout” muis model. Deze muizen zijn 
gemodificeerd zodat zij, net als de 
tenascine-X deficiënte patiënten, geen 
tenascin-X eiwit kunnen maken.  
In hoofdstuk 2 hebben we laten 
zien dat de huid van de tenascine-X 
“knockout” muis van jongs af aan al 
zwakker is dan die van een normale muis. 
Vreemd genoeg zijn er bij de tenascine-X 
“knockout” muizen geen aanwijzingen 
gevonden voor overbeweeglijke 
gewrichten, zoals bij de tenascine-X 
deficiënte patiënten wel het geval is 
(hoofdstuk 2). Ook lijken de afwijkingen 
van baarmoederweefsel van tenascine-X 
“knockout” muizen minder dan bij 
tenascine-X deficiënte patiënten 
(hoofdstuk 4). Over het algemeen lijken 
de tenascine-X “knockout” muizen minder 
complicaties te hebben dan de tenascine-
X deficiënte patiënten. We kunnen dan 
ook stellen dat de tenascine-X deficiëntie 
bij de mens een grotere impact heeft dan 
bij de muis. Eerder was deze zwakkere 
huid al beschreven voor volwassen 
muizen door de Amerikaanse 
wetenschappers waarmee is 
samengewerkt. Zij dachten dat dit 
veroorzaakt werd door een verstoring van 
de collageen depositie in de huid. Uit onze 
studie bleek dit niet het geval te zijn, 
omdat de belangrijkste collageen eiwitten 
in de huid, type I, III en V, al vóór 
tenascine-X aanwezig lijken te zijn. Ook 
vonden wij geen verminderde dichtheid 
van collageen in de huid. Dit werd door 
middel van een andere methode door 
Japanse wetenschappers nogmaals 
bevestigd. Bij veranderingen in volwassen 
bindweefsel, zoals bij wondgenezing in de 
huid (hoofdstuk 3) en in de 
baarmoederwand tijdens zwangerschap 
(hoofdstuk 4), vonden we geen 
afwijkingen in collageen depositie. Bij 
wondgenezing waren de collageen 
eiwitten ook weer eerder aanwezig dan 
tenascine-X, wat bevestigt dat tenascin-X 
nooit bij de initiële depositie van het 
collageen betrokken kan zijn. Een 
interessante bevinding was dat het 
wondgebied in toenemende mate kracht 
kon weerstaan nadat tenascine-X in de 
extracellulaire matrix tot expressie kwam. 
De afwijkingen in elastische vezels, 
hoewel niet precies gelijk aan die in de 
mens, werden pas op latere leeftijd 
zichtbaar (hoofdstuk 2 en 4). Ook zijn de 
hoofdcomponenten van elastische vezels, 
zoals het eiwit elastine, al veel eerder 
aanwezig in de ontwikkeling van de 
extracellulaire matrix van de huid dan 
tenascine-X. Wel geldt dat tenascine-X 
eiwit, wanneer het eenmaal in de 
extracellulaire matrix tot expressie komt, 
op dezelfde plek zit (= co-lokalisatie) als 
verschillende collageen componenten en 
elastine. 
Om te bestuderen of tenascine-X 
ook een fysieke interactie kan aangaan 
met de componenten van de 
extracellulaire matrix waar het mee co-
lokaliseert zijn er verschillende 
bindingsstudies uitgevoerd. In hoofdstuk 
5 wordt de binding van het 29ste 
fibronectine domein in tenascine-X aan 
elastine en collageen type I, III en V 
aangetoond en de binding van het 
fibrinogeen domein in tenascine-X aan 
elastine beschreven. In hoofdstuk 6 wordt 
de binding van tenascine-X aan collageen 
type XII onderzocht en zijn de domeinen 
die verantwoordelijk zijn voor deze 
interactie in beide eiwitten geïdentificeerd. 
Collageen type XII zit aan collageen 
bundels en kan in samenwerking met 
tenascine-X een verbinding vormen tussen 
collageen bundels. Tijdens en voor het 
schrijven van dit proefschrift hebben 
andere wetenschappers aangetoond dat 
tenascine-X ook aan andere componenten 
van de extracellulaire matrix en cellen kan 
binden. Al deze informatie en de 
bevindingen uit hoofdstukken 2 tm 6 
hebben geleid tot de theorie dat tenascine-
X als een soort lijm een aantal belangrijke 
componenten van de extracellulaire matrix 
aan elkaar verbindt en zo de 
extracellulaire matrix stabiliteit geeft.  
Niet alleen in de extracellulaire 
matrix van veel weefsels komt tenascine-X 
voor maar er is ook een fragment van 140 
kDa aanwezig in het bloed van gezonde 
mensen. Over dit fragment was weinig 
bekend behalve dat het waarschijnlijk 
gedeeltelijk overeenkomstig was met het 
C-terminale deel (uiteinde) van het 
volledige tenascine-X (450 kDa). Om te 
bestuderen welk gedeelte van het 
volledige eiwit dit fragment nu precies was  
en welke parameters belangrijk waren bij 
de gemeten hoeveelheid van dit fragment 
in het bloed, zijn er verschillende nieuwe 
antilichamen tegen tenascine-X ontwikkeld 
(hoofdstuk 7). Uiteindelijk bleek dat er 
niet één maar veel meer fragmenten in 
bloed aanwezig waren. Ook bleek dat 
jonge kinderen een hogere waarde 
hadden dan volwassenen. Verder viel op 
dat bij opslag van het afgenomen bloed de 
gemeten waarde sterk terugliep, zelfs bij -
20°C. Bij het correleren van ziektebeelden 
aan gemeten tenascine-X waarden in 
bloed, moet hier zeer zeker rekening mee 
worden gehouden. Na zuivering van 
tenascine-X fragmenten uit bloed met 
behulp van antilichamen tegen de C-
terminus van tenascine-X, blijken twee 
fragmenten, van ~75 kDa en van ~140-
150 kDa, het meest voor te komen. Deze 
fragmenten tonen nog biologische activiteit 
in de vorm van binding aan elastine. 
 De resultaten beschreven in dit 
proefschrift laten zien dat tenascine-X een 
belangrijke functie heeft in de stabiliteit 
van de extracellulaire matrix en dat het 
niet betrokken is bij de initiële depositie 
ervan. Onze bevindingen over tenascine-X 
in bloed kunnen als richtlijnen gelden bij 
onderzoek naar de betrokkenheid van dit 
eiwit in andere ziektebeelden. Ook het 
uitzoeken van de domeinen in tenascine-X 
die interacties met andere eiwitten kunnen 
aangaan, vormt een mooie basis voor 
onderzoek naar gebruik van deze 
domeinen als peptide bij bijvoorbeeld 
wondgenezing. Tenslotte is de interactie 
van tenascine-X met collageen type XII 
erg interessant. De genetische oorzaken 
van het Ehlers-Danlos syndroom zijn bij 
veel patiënten nog niet opgehelderd, 
mogelijk zou een afwijking in collageen 
type XII een gedeelte hiervan kunnen 
verklaren.  
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CHAPTER 2 
 
 
Figure 2: TNX immunofluorescent staining of the developing skin of wild-type mice.  
(a) At stage E14, no significant signal in the prospective dermis is detected (blue nuclear staining with DAPI). (b) 
By stage E15, TNX expression (green) is visible in the developing reticular dermis and around the fascia of the 
carnosus muscle layer. (c, e) At E18 and in 1-day-old neonatal mice, respectively, expression of TNX has 
extended further into the dermis. (d) Higher magnification of the rectangle in (c); TNX is expressed in the fetal 
mouse in a distinct fibre-like pattern. (f) In adult mouse skin, TNX is observed throughout the dermis in a more 
homogeneous pattern. (g) Higher magnification of the rectangle in (f). (h) The specificity of the anti-TNX serum is 
demonstrated in TNX knockout mice skin (E18), which is devoid of signal. Bars 50 µm (a–c, e, f, h), 25 µm (d, g). 
 
 
Figure 3: Merged micrographs showing immunofluorescent doublestaining for TNX (green) and collagens 
(red) type I (a, d, g, j,m), III (b, e, h, k, n), or V (c, f, i, l, o) in developing skin of wild-type mice.  
Nuclei are stained blue with DAPI. The different types of collagen are expressed even at fetal stages E10 (a–c) 
and E14 (d–f) in the prospective dermis. At E18 (g–i) and 1-day-old neonatal (1 day Neo.) mice (j–l), TNX starts to 
colocalize with the various types of collagens (orange, yellow). In adult mice, TNX is expressed in the entire 
dermis and overlaps with collagens type I (m), III (n), and V (o). Non-specific staining of the stratum corneum was 
present in some sections. Bars 50 µm. 
 
 
 
Figure 4: Merged micrographs of immunofluorescent double-staining for TNX (green) and tropoelastin 
(TE; red) in developing skin in wild-type mice.  
TE is expressed in the undifferentiated mesenchyme at the earliest investigated stage, E10 (a). The signals for 
TE and TNX partially overlap (orange, yellow) in the developing mice skin around the fascia of the carnosus 
muscle at E18 (b). In adult mice (c), the entire dermis is stained positively for TNX with overlapping signal for TE 
(orange, yellow). Bars 50 µm. 
 
 
 
Figure 5: Analysis of elastin and elastic fibers. Immunostaining for TE on paraffin sections of 9-month-old 
mice (a–c). 
At 3–6 months, TNX knockout mice (c) show a higher density of TE in their dermis than do wild-type (a) and 
heterozygous (b) mice (represented graphically in e). The density of mature elastic fibers made visible by 
modified Hart’s staining in TNX knockout skin (not shown) compared with wild-type mice (d) is increased (f). No 
differences in desmosine content expressed per milligram protein (h) or per mm2 (g) skin were found between the 
different phenotypes in adult mice. *P<0.01, **P<0.05, + not significant. For all comparisons, n=12 for each 
genotype for mice at 3–6 months, n=6 (or more) for mice at 2 weeks and 9 months. For 2-month-old mice, n=8 for 
heterozygous mice, n=4 for TNX knockout mice and n=3 for wild-type mice (KO knockout, WT wild-type, +/− 
heterozygous). 
CHAPTER 3 
 
Figure 1: Widened scar in TNX 
deficient patient.  
An example of a widened scar with 
irregular boundaries, indicated by 
arrows, on the arm of a TNX-
deficient patient. This is found in 
some of our TNX-deficient patients, 
but not in all patients. Atrophic scars 
(cigarette paper-like skin) were 
never observed in these patients. 
 
 
 
 
Figure 3: Low expression of TNX and absence of elastic fibers in wound tissue.  
White arrows indicate the wound area in sections (a) and (b). Red arrows indicate uninjured skin. TNX expression 
is very low/not present in a 7-day-old wound area of WT skin (a). TNX expression (green) can be observed in a 
14-day-old wound area of WT skin but it is far less strong than in the adjacent normal skin (b). The specificity of 
the anti-TNX antibody is demonstrated in TNX KO skin, which is devoid of signal (c). Note that staining of the 
stratum corneum is nonspecific (a–c). No elastic fibers can be detected in a 14-day-old wound area as shown by 
modified Hart’s staining for WT skin (d) and TNX KO skin. Black arrows indicate the wound area, white. Bars in 
(a), (b), (d), and (e) are 100 µm and 50 µm in (c). 
 
Figure 2: Collagen distribution in the wound area. 
In (a) and (b) collagen is stained red/pink by Sirius red staining. The wound area is indicated by black arrows. The 
collagen fibrils in the dermis under the wound area are packed less tight compared with uninjured skin (indicated 
by grey arrows). No obvious differences in collagen density in the wound area between WT (a) and TNX KO (b) 
mice were noted as is shown for a 14-day-old wound area. Immunofluorescent staining (red) of collagen type I (c, 
f), III (d, g) and V (e, h) are abundantly expressed in a 7-day (c–e) and 14-day (f–h) wound area (as shown for WT 
skin). The area under white arrows indicates the wounded skin. Hair follicles are absent in the wound area but 
present in uninjured skin. Positive staining of the outer layer of the epidermis (stratum corneum) is nonspecific. 
Bars in (a, b) are 25 µm, bars in (c-h) are 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
 
 
Figure 1: TNX KO mice abnormalities. 
(a) Although the difference in the length of pregnancy between TNX KO and WT mice is found non-significant by 
Fisher exact test, a decreasing trend in the length of pregnancy of TNX KO mouse compared to WT mice can be 
observed. Vaginal plugs, which are present after mating, are much more difficult to asses in TNX KO mice than in 
WT mice. This results in a significant increase of pregnancies in which the insemination date was unknown as 
shown in panel (b). In this study no uterine prolapses have been observed, however, some TNX KO mice suffer 
from a rectal prolapse as shown in panel (c). Rectal prolapses are also observed in TNX-deficient patients, 
although the incidence in TNX KO mouse appears low. (* p<0.025, chi square test).  
 
 
 
Figure 2: Structure of the TNX KO and WT uterus. 
H&E stained sections of the uterus of WT mice (a) and of TNX KO mice (b) are shown. No differences in structure 
of the uterus were noticeable between TNX KO and WT mice. The uterus of mice consists of a thin outer layer, 
the perimetrium (denoted as P). A muscle layer, the myometrium (denoted as M), consist of two oppositely 
orientated layers of muscle, although this is difficult to distinguish in H&E stained slides. The endometrium 
(denoted as E) consist of loose connective tissue. The endometrium is separated from the lumen (denoted as L) 
by an epithelium. Bars are 0.01 mm. 
  
 
Figure 3: Immunostaining of TNX in the uterus. 
TNX (green) is present throughout the uterus of virgin mice (a) and in the uterus during and after pregnancy 
(shown for 13 days pregnant (b) and 3 weeks postpartum (c) uteri). Cell nuclei are stained with DAPI (blue). TNX 
is present in the endometrium (d) and the layers of connective tissue ensheathing muscle bundles of the 
myometrium (f). The TNX staining of the perimetrium can be relatively weak (a-c and f). The epithelium of the 
lumen is negative for TNX (d). Specificity of our TNX antibody is demonstrated in figures (e) and (g). Panels (d-g) 
are from uteri 3 weeks postpartum. Bars are 50 µm (P = perimetrium, M = myometrium; longtidunal muscle 
bundles, M* = myometrium; transverse muscle bundles, E = endometrium, Epi = epithelium of the lumen, L = 
lumen). 
 
 
 
 
 
 
 
  
 
Figure 4: TNX colocalizes with major fibrillar collagens type I, III and V. 
TNX (green) and collagen types I (a), III (b) and V (c) (red) colocalize (yellow to orange) as is shown for uteri 3 
weeks postpartum. Similar results were obtained for uteri from virgin, 13 days pregnant and 1-day postpartum 
mice. No difference in collagen type I, III and V immunostaining was found between WT and TNX KO mice (data 
not shown). Bars are 50 µm (P = perimetrium, M = myometrium; longtidunal muscle bundles, M* = myometrium; 
transverse muscle bundles, E = endometrium, Epi = epithelium of the lumen, L = lumen). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5: Immunostaining of collagen type XII in uterus. 
Collagen XII (red) is present throughout the uterus. The immunostaining appears the strongest in the transverse 
muscle bundles of the myometrium (M*), around blood vessels (BV) and around the lumen (L), although the 
signal intensity is not always completely continuous. No differences in the collagen type XII localization in the 
uterus between WT (a) and TNX KO (b) mice were observed. Bars are 50 µm (P = perimetrium, M = myometrium; 
longtidunal muscle bundles, M* = myometrium; transverse muscle bundles, BV = blood vessel, E = endometrium, 
L = lumen). 
 
 
Figure 6: Elastin and elastic fibers in the uterus. 
Elastic fibers (purple, modified Hart’s staining) are mostly located in the myometrium (M, M*) and perimetrium (P), 
whereas the endometrium (E) appears to contain fewer elastic fibers as shown for WT (a) and TNX KO mice (b). 
No elastic fiber abnormalities were found in the TNX KO mice. Elastin (red) immunostaining is observed in the 
myometrium, predominantly in the transverse bundles (M*) as shown in panels (c) and (d). The layers of 
connective tissue ensheathing muscle bundles of the myometrium (M) and perimetrium (P) are stained positive 
for elastin (red). Strong elastin staining is also seen in the endometrium (E). Elastin immunoreactivity was similar 
for WT (c) and TNX KO mice (d). Elastin (red) colocalizes (orange) with TNX (green) as shown in the myometrium 
(M*) (e). Not all TNX colocalizes with elastin as TNX also colocalizes with different collagen types (fig. 4). Bars 
are 50 µm (P = perimetrium, M = myometrium; longtidunal muscle bundles, M* = myometrium; transverse muscle 
bundles, BV = blood vessel, E = endometrium, L = lumen). 
 
